Experimental transplantation of neoplasms in laboratory animals for research purposes.
The transference of a part of or an entire liver from one human or animal to another.
Transplantation between individuals of the same species. Usually refers to genetically disparate individuals in contradistinction to isogeneic transplantation for genetically identical individuals.
The transference of a kidney from one human or animal to another.
The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION.
Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms.
The transference of a heart from one human or animal to another.
Transplantation of an individual's own tissue from one site to another site.
The transference of either one or both of the lungs from one human or animal to another.
The transfer of STEM CELLS from one individual to another within the same species (TRANSPLANTATION, HOMOLOGOUS) or between species (XENOTRANSPLANTATION), or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). The source and location of the stem cells determines their potency or pluripotency to differentiate into various cell types.
Preparative treatment of transplant recipient with various conditioning regimens including radiation, immune sera, chemotherapy, and/or immunosuppressive agents, prior to transplantation. Transplantation conditioning is very common before bone marrow transplantation.
Transference of an organ between individuals of the same species or between individuals of different species.
The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host.
An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient.
The transference of a pancreas from one human or animal to another.
The transference of pancreatic islets within an individual, between individuals of the same species, or between individuals of different species.
Individuals supplying living tissue, organs, cells, blood or blood components for transfer or transplantation to histocompatible recipients.
Transference of a tissue or organ from either an alive or deceased donor, within an individual, between individuals of the same species, or between individuals of different species.
A general term for the complex phenomena involved in allo- and xenograft rejection by a host and graft vs host reaction. Although the reactions involved in transplantation immunology are primarily thymus-dependent phenomena of cellular immunity, humoral factors also play a part in late rejection.
Transference of cells within an individual, between individuals of the same species, or between individuals of different species.
An organism that, as a result of transplantation of donor tissue or cells, consists of two or more cell lines descended from at least two zygotes. This state may result in the induction of donor-specific TRANSPLANTATION TOLERANCE.
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Transplantation between genetically identical individuals, i.e., members of the same species with identical histocompatibility antigens, such as monozygotic twins, members of the same inbred strain, or members of a hybrid population produced by crossing certain inbred strains.
The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.
Non-cadaveric providers of organs for transplant to related or non-related recipients.
Transplantation of tissue typical of one area to a different recipient site. The tissue may be autologous, heterologous, or homologous.
Transplantation of STEM CELLS collected from the fetal blood remaining in the UMBILICAL CORD and the PLACENTA after delivery. Included are the HEMATOPOIETIC STEM CELLS.
The simultaneous, or near simultaneous, transference of heart and lungs from one human or animal to another.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.
The administrative procedures involved with acquiring TISSUES or organs for TRANSPLANTATION through various programs, systems, or organizations. These procedures include obtaining consent from TISSUE DONORS and arranging for transportation of donated tissues and organs, after TISSUE HARVESTING, to HOSPITALS for processing and transplantation.
An induced state of non-reactivity to grafted tissue from a donor organism that would ordinarily trigger a cell-mediated or humoral immune response.
Elements of limited time intervals, contributing to particular results or situations.
Transplantation of stem cells collected from the peripheral blood. It is a less invasive alternative to direct marrow harvesting of hematopoietic stem cells. Enrichment of stem cells in peripheral blood can be achieved by inducing mobilization of stem cells from the BONE MARROW.
Severe inability of the LIVER to perform its normal metabolic functions, as evidenced by severe JAUNDICE and abnormal serum levels of AMMONIA; BILIRUBIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; LACTATE DEHYDROGENASES; and albumin/globulin ratio. (Blakiston's Gould Medical Dictionary, 4th ed)
Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs.
Identification of the major histocompatibility antigens of transplant DONORS and potential recipients, usually by serological tests. Donor and recipient pairs should be of identical ABO blood group, and in addition should be matched as closely as possible for HISTOCOMPATIBILITY ANTIGENS in order to minimize the likelihood of allograft rejection. (King, Dictionary of Genetics, 4th ed)
Transference of fetal tissue between individuals of the same species or between individuals of different species.
Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.
The grafting of skin in humans or animals from one site to another to replace a lost portion of the body surface skin.
Neoplasms containing cyst-like formations or producing mucin or serum.
Transplantation between animals of different species.
The return of a sign, symptom, or disease after a remission.
Prospective patient listings for appointments or treatments.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
Transfer of MESENCHYMAL STEM CELLS between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS).
Partial or total replacement of the CORNEA from one human or animal to another.
The degree of antigenic similarity between the tissues of different individuals, which determines the acceptance or rejection of allografts.
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro.
Transference of tissue within an individual, between individuals of the same species, or between individuals of different species.
Tumors or cancer of the LIVER.
Irradiation of the whole body with ionizing or non-ionizing radiation. It is applicable to humans or animals but not to microorganisms.
A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed).
Tumors or cancer of the SKIN.
A dead body, usually a human body.
Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.
A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)
Pathological processes of the LIVER.
Transference of brain tissue, either from a fetus or from a born individual, between individuals of the same species or between individuals of different species.
Two or more abnormal growths of tissue occurring simultaneously and presumed to be of separate origin. The neoplasms may be histologically the same or different, and may be found in the same or different sites.
The transference between individuals of the entire face or major facial structures. In addition to the skin and cartilaginous tissue (CARTILAGE), it may include muscle and bone as well.
The procedure established to evaluate the health status and risk factors of the potential DONORS of biological materials. Donors are selected based on the principles that their health will not be compromised in the process, and the donated materials, such as TISSUES or organs, are safe for reuse in the recipients.
The process by which organs are kept viable outside of the organism from which they were removed (i.e., kept from decay by means of a chemical agent, cooling, or a fluid substitute that mimics the natural state within the organism).
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
Tumors or cancers of the KIDNEY.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
An alkylating agent having a selective immunosuppressive effect on BONE MARROW. It has been used in the palliative treatment of chronic myeloid leukemia (MYELOID LEUKEMIA, CHRONIC), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
Organs, tissues, or cells taken from the body for grafting into another area of the same body or into another individual.
Antigens determined by leukocyte loci found on chromosome 6, the major histocompatibility loci in humans. They are polypeptides or glycoproteins found on most nucleated cells and platelets, determine tissue types for transplantation, and are associated with certain diseases.
A general term for various neoplastic diseases of the lymphoid tissue.
The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.
Inflammation of the BRONCHIOLES leading to an obstructive lung disease. Bronchioles are characterized by fibrous granulation tissue with bronchial exudates in the lumens. Clinical features include a nonproductive cough and DYSPNEA.
Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept.
Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body.
Therapeutic act or process that initiates a response to a complete or partial remission level.
Tumors or cancer of the THYROID GLAND.
Serum containing GAMMA-GLOBULINS which are antibodies for lymphocyte ANTIGENS. It is used both as a test for HISTOCOMPATIBILITY and therapeutically in TRANSPLANTATION.
Disease having a short and relatively severe course.
An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed)
Progenitor cells from which all blood cells derive.
The period following a surgical operation.
The transference of a complete HAND, as a composite of many tissue types, from one individual to another.
A form of anemia in which the bone marrow fails to produce adequate numbers of peripheral blood elements.
A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
An antigenic mismatch between donor and recipient blood. Antibodies present in the recipient's serum may be directed against antigens in the donor product. Such a mismatch may result in a transfusion reaction in which, for example, donor blood is hemolyzed. (From Saunders Dictionary & Encyclopedia of Laboratory Medicine and Technology, 1984).
Infection with CYTOMEGALOVIRUS, characterized by enlarged cells bearing intranuclear inclusions. Infection may be in almost any organ, but the salivary glands are the most common site in children, as are the lungs in adults.
An antibiotic substance derived from Penicillium stoloniferum, and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase. Mycophenolic acid is important because of its selective effects on the immune system. It prevents the proliferation of T-cells, lymphocytes, and the formation of antibodies from B-cells. It also may inhibit recruitment of leukocytes to inflammatory sites. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1301)
Tumors or cancer of the LUNG.
Agents that destroy bone marrow activity. They are used to prepare patients for BONE MARROW TRANSPLANTATION or STEM CELL TRANSPLANTATION.
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.
DNA present in neoplastic tissue.
The procedure of removing TISSUES, organs, or specimens from DONORS for reuse, such as TRANSPLANTATION.
Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms.
A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
The number of new cases of a given disease during a given period in a specified population. It also is used for the rate at which new events occur in a defined population. It is differentiated from PREVALENCE, which refers to all cases, new or old, in the population at a given time.
Neoplasms associated with a proliferation of a single clone of PLASMA CELLS and characterized by the secretion of PARAPROTEINS.
Final stage of a liver disease when the liver failure is irreversible and LIVER TRANSPLANTATION is needed.
Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs.
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.
Criteria and standards used for the determination of the appropriateness of the inclusion of patients with specific conditions in proposed treatment plans and the criteria used for the inclusion of subjects in various clinical trials and other research protocols.
Tumors or cancer of the PAROTID GLAND.
Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.
A benign neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. In some instances, considerable portions of the neoplasm, or even the entire mass, may be cystic. (Stedman, 25th ed)
Neoplasms developing from some structure of the connective and subcutaneous tissue. The concept does not refer to neoplasms located in connective or soft tissue.
A state of prolonged irreversible cessation of all brain activity, including lower brain stem function with the complete absence of voluntary movements, responses to stimuli, brain stem reflexes, and spontaneous respirations. Reversible conditions which mimic this clinical state (e.g., sedative overdose, hypothermia, etc.) are excluded prior to making the determination of brain death. (From Adams et al., Principles of Neurology, 6th ed, pp348-9)
The application of probability and statistical methods to calculate the risk of occurrence of any event, such as onset of illness, recurrent disease, hospitalization, disability, or death. It may include calculation of the anticipated money costs of such events and of the premiums necessary to provide for payment of such costs.
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
Tumors or cancer of the APPENDIX.
Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.
An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.
A form of rapid-onset LIVER FAILURE, also known as fulminant hepatic failure, caused by severe liver injury or massive loss of HEPATOCYTES. It is characterized by sudden development of liver dysfunction and JAUNDICE. Acute liver failure may progress to exhibit cerebral dysfunction even HEPATIC COMA depending on the etiology that includes hepatic ISCHEMIA, drug toxicity, malignant infiltration, and viral hepatitis such as post-transfusion HEPATITIS B and HEPATITIS C.
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
Cells contained in the bone marrow including fat cells (see ADIPOCYTES); STROMAL CELLS; MEGAKARYOCYTES; and the immediate precursors of most blood cells.
Tumors or cancer of the ENDOCRINE GLANDS.
A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.
Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
A multilocular tumor with mucin secreting epithelium. They are most often found in the ovary, but are also found in the pancreas, appendix, and rarely, retroperitoneal and in the urinary bladder. They are considered to have low-grade malignant potential.
Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
Disorders characterized by proliferation of lymphoid tissue, general or unspecified.
Tumors or cancer of the GASTROINTESTINAL TRACT, from the MOUTH to the ANAL CANAL.
Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.
A form of ischemia-reperfusion injury occurring in the early period following transplantation. Significant pathophysiological changes in MITOCHONDRIA are the main cause of the dysfunction. It is most often seen in the transplanted lung, liver, or kidney and can lead to GRAFT REJECTION.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
The occurrence in an individual of two or more cell populations of different chromosomal constitutions, derived from different individuals. This contrasts with MOSAICISM in which the different cell populations are derived from a single individual.
The major human blood type system which depends on the presence or absence of two antigens A and B. Type O occurs when neither A nor B is present and AB when both are present. A and B are genetic factors that determine the presence of enzymes for the synthesis of certain glycoproteins mainly in the red cell membrane.
Glycoproteins found on immature hematopoietic cells and endothelial cells. They are the only molecules to date whose expression within the blood system is restricted to a small number of progenitor cells in the bone marrow.
Tumors or cancer of the EYE.
Tumors or cancer of the BILE DUCTS.
Relatively undifferentiated cells that retain the ability to divide and proliferate throughout postnatal life to provide progenitor cells that can differentiate into specialized cells.
A short thick vein formed by union of the superior mesenteric vein and the splenic vein.
Tumors, cancer or other neoplasms produced by exposure to ionizing or non-ionizing radiation.
Immunological rejection of leukemia cells following bone marrow transplantation.
Tumors or cancer of the TESTIS. Germ cell tumors (GERMINOMA) of the testis constitute 95% of all testicular neoplasms.
A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.
General dysfunction of an organ occurring immediately following its transplantation. The term most frequently refers to renal dysfunction following KIDNEY TRANSPLANTATION.
Excision of all or part of the liver. (Dorland, 28th ed)
Invasion of the host organism by microorganisms that can cause pathological conditions or diseases.
Tumors or cancer of the NOSE.
Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.
The transfer of lymphocytes from a donor to a recipient or reinfusion to the donor.
Neoplasms composed of muscle tissue: skeletal, cardiac, or smooth. The concept does not refer to neoplasms located in muscles.
Immunosuppression by reduction of circulating lymphocytes or by T-cell depletion of bone marrow. The former may be accomplished in vivo by thoracic duct drainage or administration of antilymphocyte serum. The latter is performed ex vivo on bone marrow before its transplantation.
The release of stem cells from the bone marrow into the peripheral blood circulation for the purpose of leukapheresis, prior to stem cell transplantation. Hematopoietic growth factors or chemotherapeutic agents often are used to stimulate the mobilization.
Progressive destruction or the absence of all or part of the extrahepatic BILE DUCTS, resulting in the complete obstruction of BILE flow. Usually, biliary atresia is found in infants and accounts for one third of the neonatal cholestatic JAUNDICE.
The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells.
Neoplasms composed of vascular tissue. This concept does not refer to neoplasms located in blood vessels.
Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.
Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
Neoplasms composed of glandular tissue, an aggregation of epithelial cells that elaborate secretions, and of any type of epithelium itself. The concept does not refer to neoplasms located in the various glands or in epithelial tissue.
The chilling of a tissue or organ during decreased BLOOD perfusion or in the absence of blood supply. Cold ischemia time during ORGAN TRANSPLANTATION begins when the organ is cooled with a cold perfusion solution after ORGAN PROCUREMENT surgery, and ends after the tissue reaches physiological temperature during implantation procedures.
Tumors or cancer of the SALIVARY GLANDS.
Tomography using x-ray transmission and a computer algorithm to reconstruct the image.
The development and formation of various types of BLOOD CELLS. Hematopoiesis can take place in the BONE MARROW (medullary) or outside the bone marrow (HEMATOPOIESIS, EXTRAMEDULLARY).
A nonparametric method of compiling LIFE TABLES or survival tables. It combines calculated probabilities of survival and estimates to allow for observations occurring beyond a measurement threshold, which are assumed to occur randomly. Time intervals are defined as ending each time an event occurs and are therefore unequal. (From Last, A Dictionary of Epidemiology, 1995)
Liver disease that is caused by injuries to the ENDOTHELIAL CELLS of the vessels and subendothelial EDEMA, but not by THROMBOSIS. Extracellular matrix, rich in FIBRONECTINS, is usually deposited around the HEPATIC VEINS leading to venous outflow occlusion and sinusoidal obstruction.
Surgical union or shunt between ducts, tubes or vessels. It may be end-to-end, end-to-side, side-to-end, or side-to-side.
Antibodies from an individual that react with ISOANTIGENS of another individual of the same species.
Disorders of the blood and blood forming tissues.
Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.
An adenocarcinoma containing finger-like processes of vascular connective tissue covered by neoplastic epithelium, projecting into cysts or the cavity of glands or follicles. It occurs most frequently in the ovary and thyroid gland. (Stedman, 25th ed)
Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.
Immunological rejection of tumor tissue/cells following bone marrow transplantation.
A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)
A benign epithelial tumor with a glandular organization.
Tumors or cancer of the SPLEEN.
A set of techniques used when variation in several variables has to be studied simultaneously. In statistics, multivariate analysis is interpreted as any analytic method that allows simultaneous study of two or more dependent variables.
Body organ that filters blood for the secretion of URINE and that regulates ion concentrations.
Antibodies produced by a single clone of cells.
The period of care beginning when the patient is removed from surgery and aimed at meeting the patient's psychological and physical needs directly after surgery. (From Dictionary of Health Services Management, 2d ed)
Tumors or cancer of the INTESTINES.
Providers of tissues for transplant to non-related individuals.
Tumors or cancer located in bone tissue or specific BONES.
Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.
Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.
A nucleoside antibiotic isolated from Streptomyces antibioticus. It has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the herpes viruses, the VACCINIA VIRUS and varicella zoster virus.
The qualitative or quantitative estimation of the likelihood of adverse effects that may result from exposure to specified health hazards or from the absence of beneficial influences. (Last, Dictionary of Epidemiology, 1988)
A malignant cystic or semisolid tumor most often occurring in the ovary. Rarely, one is solid. This tumor may develop from a mucinous cystadenoma, or it may be malignant at the onset. The cysts are lined with tall columnar epithelial cells; in others, the epithelium consists of many layers of cells that have lost normal structure entirely. In the more undifferentiated tumors, one may see sheets and nests of tumor cells that have very little resemblance to the parent structure. (Hughes, Obstetric-Gynecologic Terminology, 1972, p184)
Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time.
Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.
Neoplasms located in the vasculature system, such as ARTERIES and VEINS. They are differentiated from neoplasms of vascular tissue (NEOPLASMS, VASCULAR TISSUE), such as ANGIOFIBROMA or HEMANGIOMA.
Non-human animals, selected because of specific characteristics, for use in experimental research, teaching, or testing.
A therapeutic approach, involving chemotherapy, radiation therapy, or surgery, after initial regimens have failed to lead to improvement in a patient's condition. Salvage therapy is most often used for neoplastic diseases.
Tumors or cancer of the UTERUS.
An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed)
Ability of neoplasms to infiltrate and actively destroy surrounding tissue.
A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.

Classification of human colorectal adenocarcinoma cell lines. (1/10282)

Eleven human colorectal adenocarcinoma cell lines established in this laboratory were classified into three groups based on morphological features (light and electron microscopy), modal chromosome number, and ability to synthesize carcinoembryonic antigen (CEA). Group 1 cell lines contained both dedifferentiated and differentiating cells growing in tight clusters or islands of epithelium-like cells; their modal chromosome number was about 47, and they synthesized small to moderate amounts of CEA. Group 2 cell lines were more dedifferentiated, were hyperdiploid, and synthesized small amounts of CEA. Group 3 cell lines were morphologically similar to those of Group 1 by light microscopy. They differed ultrastructurally by containing microvesicular bodies; the modal chromosome number varied from hyperdiploid to hypertriploid or they had bimodal populations of hypodiploid and hypertriploid cells, and they synthesized relatively large amounts of CEA. No correlation could be found between Broder's grade or Duke's classification of the original tumor and modal chromosome number or ability to synthesize CEA. These findings support Nowell's hypothesis that the stem line is different for each solid tumor, which makes it difficult to relate chromosomal changes to the initiation of the neoplastic state.  (+info)

Long-term transplantability and morphological stability of three experimentally induced urinary bladder carcinomas in rats. (2/10282)

Three transitional cell carcinomas induced in Fischer 344 rats by a methylcholanthrene pellet or a foreign body inserted locally into the bladder have been serially transplanted in the syngeneic strain for up to 6.5 years. There have been no changes in the individual morphological characteristics of the tumors during this time. Cells cultured in vitro for varying numbers of passages reproduce regularly the morphology of each tumor when they are injected back into the animals and results from a microcytotoxicity assay for cellular immunity indicate that they retain a common, bladder tumor-specific antigen. These tumors are useful for research in turmo biology and are offered to other scientists seeking transplantable carcinomas for experimentation.  (+info)

Natural history of papillary lesions of the urinary bladder in schistosomiasis. (3/10282)

Variable epithelial hyperplasia was observed in urinary bladder of nine capuchin monkeys (Cebus apella) when examined at cystotomy 94 to 164 weeks after infection with Schistosoma haematobium. These hosts were followed for 24 to 136 weeks postcystotomy to determine the status of bladder lesions in relation to duration of infection and to ascertain whether lesion samples removed at cystotomy reestablished themselves in autologous and heterologous transfers. There was involution of urothelial hyperplasia in eight of nine animals and no evidence for establishment of transplanted bladder lesions.  (+info)

Antitumor effect of allogenic fibroblasts engineered to express Fas ligand (FasL). (4/10282)

Fas ligand is a type II transmembrane protein which can induce apoptosis in Fas-expressing cells. Recent reports indicate that expression of FasL in transplanted cells may cause graft rejection and, on the other hand, tumor cells may lose their tumorigenicity when they are engineered to express FasL. These effects could be related to recruitment of neutrophils by FasL with activation of their cytotoxic machinery. In this study we investigated the antitumor effect of allogenic fibroblasts engineered to express FasL. Fibroblasts engineered to express FasL (PA317/FasL) did not exert toxic effects on transformed liver cell line (BNL) or colon cancer cell line (CT26) in vitro, but they could abrogate their tumorigenicity in vivo. Histological examination of the site of implantation of BNL cells mixed with PA317/FasL revealed massive infiltration of polymorphonuclear neutrophils and mononuclear cells. A specific immune protective effect was observed in animals primed with a mixture of BNL or CT26 and PA317/FasL cells. Rechallenge with tumor cells 14 or 100 days after priming resulted in protection of 100 or 50% of animals, respectively. This protective effect was due to CD8+ cells since depletion of CD8+ led to tumor formation. In addition, treatment of pre-established BNL tumors with a subcutaneous injection of BNL and PA317/FasL cell mixture at a distant site caused significant inhibition of tumor growth. These data demonstrate that allogenic cells engineered with FasL are able to abolish tumor growth and induce specific protective immunity when they are mixed with neoplastic cells.  (+info)

Mechanisms related to [18F]fluorodeoxyglucose uptake of human colon cancers transplanted in nude mice. (5/10282)

[18F]Fluorodeoxyglucose ([18F]FDG), a glucose analogue, has been widely used for tumor imaging. To investigate the mechanisms related to [18F]FDG uptake by tumors, an experiment involving nude mice was performed. METHODS: Human colon cancer cell lines SNU-C2A, SNU-C4 and SNU-C5 were transplanted to nude mice. Using immunohistochemical staining and Western blot, the expression of glucose transporter (Glut) isoforms (Glut-1 through -5) in xenografted tumors was analyzed. For the analysis of messenger ribonucleic acid (mRNA) expression, reverse-transcription polymerase chain reaction and Northern blot were used and the enzyme activity of hexokinase in cancer tissues was measured by continuous spectrophotometric rate determination. RESULTS: [18F]FDG uptake in SNU-C4 and SNU-C5 cells was higher than in normal colon cells. Among these cells and xenografted tumors, SNU-C5 showed the highest level of [18F]FDG uptake, followed by SNU-C4 and SNU-C2A. An immunostaining experiment showed intense staining of Glut-1 in SNU-C5 tumors but somewhat faint staining in SNU-C4. SNU-C5 tumors also showed positive staining with Glut-3, although this was not the case with SNU-C2A and SNU-C4. Western blot analysis showed the expression of Glut-1 and Glut-3 in all tumors. Experiments involving Northern blot analysis and reverse-transcription polymerase chain reaction confirmed the overexpression of Glut-1 mRNA in all tumors, with the highest level in SNU-C5. The level of Glut-3 mRNA was also elevated in SNU-C5 tumors but not in SNU-C2A and SNU-C4. The enzyme activity of hexokinase did not vary among different tumors. CONCLUSION: Gluts, especially Glut-1, are responsible for [18F]FDG uptake in a nude mouse model of colon cancer rather than hexokinase activity. Increased numbers of glucose transporters at the plasma membrane of cancer cells is attributed to an increased level of transcripts of glucose transporter genes and may be a cause of increased [18F]FDG uptake, at least in colon cancer tumors.  (+info)

99mTc-labeled vasoactive intestinal peptide receptor agonist: functional studies. (6/10282)

Vasoactive intestinal peptide (VIP) is a naturally occurring 28-amino acid peptide with a wide range of biological activities. Recent reports suggest that VIP receptors are expressed on a variety of malignant tumor cells and that the receptor density is higher than for somatostatin. Our aims were to label VIP with 99mTc--a generator-produced, inexpensive radionuclide that possesses ideal characteristics for scintigraphic imaging--and to evaluate 99mTc-VIP for bioactivity and its ability to detect experimental tumors. METHODS: VIP28 was modified at the carboxy terminus by the addition of four amino acids that provided an N4 configuration for a strong chelation of 99mTc. To eliminate steric hindrance, 4-aminobutyric acid (Aba) was used as a spacer. VIP28 was labeled with 1251, which served as a control. Biological activity of the modified VIP28 agonist (TP3654) was examined in vitro using a cell-binding assay and an opossum internal anal sphincter (IAS) smooth muscle relaxivity assay. Tissue distribution studies were performed at 4 and 24 h after injection, and receptor-blocking assays were also performed in nude mice bearing human colorectal cancer LS174T. Blood clearance was examined in normal Sprague-Dawley rats. RESULTS: The yield of 99mTc-TP3654 was quantitative, and the yields of 125I-VIP and 1251-TP3654 were >90%. All in vitro data strongly suggested that the biological activity of 99mTc-TP3654 agonist was equivalent to that of VIP28. As the time after injection increased, radioactivity in all tissues decreased, except in the receptor-enriched tumor (P = 0.84) and in the lungs (P = 0.78). The tumor uptake (0.23 percentage injected dose per gram of tissue [%ID/g]) was several-fold higher than 125I-VIP (0.06 %ID/g) at 24 h after injection in the similar system. In mice treated with unlabeled VIP or TP3654, the uptake of 99mTc-TP3654 decreased in all VIP receptor-rich tissues except the kidneys. The blood clearance was biphasic; the alpha half-time was 5 min and the beta half-time was approximately 120 min. CONCLUSION: VIP28 was modified and successfully labeled with 99mTc. The results of all in vitro examinations indicated that the biological activity of TP3654 was equivalent to that of native VIP28 and tumor binding was receptor specific.  (+info)

In vivo isolated kidney perfusion with tumour necrosis factor alpha (TNF-alpha) in tumour-bearing rats. (7/10282)

Isolated perfusion of the extremities with high-dose tumour necrosis factor alpha (TNF-alpha) plus melphalan leads to dramatic tumour response in patients with irresectable soft tissue sarcoma or multiple melanoma in transit metastases. We developed in vivo isolated organ perfusion models to determine whether similar tumour responses in solid organ tumours can be obtained with this regimen. Here, we describe the technique of isolated kidney perfusion. We studied the feasibility of a perfusion with TNF-alpha and assessed its anti-tumour effects in tumour models differing in tumour vasculature. The maximal tolerated dose (MTD) proved to be only 1 microg TNF-alpha. Higher doses appeared to induce renal failure and a secondary cytokine release with fatal respiratory and septic shock-like symptoms. In vitro, the combination of TNF-alpha and melphalan did not result in a synergistic growth-inhibiting effect on CC 531 colon adenocarcinoma cells, whereas an additive effect was observed on osteosarcoma ROS-1 cells. In vivo isolated kidney perfusion, with TNF-alpha alone or in combination with melphalan, did not result in a significant anti-tumour response in either tumour model in a subrenal capsule assay. We conclude that, because of the susceptibility of the kidney to perfusion with TNF-alpha, the minimal threshold concentration of TNF-alpha to exert its anti-tumour effects was not reached. The applicability of TNF-alpha in isolated kidney perfusion for human tumours seems, therefore, questionable.  (+info)

Medroxyprogesterone acetate inhibits interleukin 6 secretion from KPL-4 human breast cancer cells both in vitro and in vivo: a possible mechanism of the anticachectic effect. (8/10282)

Interleukin 6 (IL-6) is a multifunctional cytokine. Recent reports suggest that circulating IL-6 secreted from tumour cells plays an important role in cancer-induced cachexia. Medroxyprogesterone acetate (MPA) has been used as an endocrine therapeutic agent for patients with breast cancer. It has been suggested that MPA decreases serum IL-6 levels and preserves the bodyweight of patients with advanced breast cancer. However, the mechanisms of action responsible for the anticachectic effect of MPA have not been elucidated. Therefore, the effects of MPA on IL-6 secretion were studied both in vitro and in vivo using a human breast cancer cell line, KPL-4, which secretes IL-6 into medium and induces cachexia when injected into female nude mice. MPA (10-1000 nM) dose-dependently decreased basal IL-6 secretion into medium, and also suppressed tumour necrosis factor (TNF-alpha)-induced IL-6 secretion. Both basal and TNF-alpha-induced IL-6 mRNA levels were dose-dependently lowered by MPA. Moreover, intramuscular injections of MPA (100 mg kg(-1) twice a week) into nude mice bearing KPL-4 transplanted tumours significantly decreased serum IL-6 levels without affecting tumour growth and preserved the bodyweight of recipient mice. These findings suggest that suppression of IL-6 secretion from tumour cells, at least in part, causes the anticachectic effect of MPA.  (+info)

Shapiro, W R.; Basler, G A.; and Posner, J B., Human brain tumor transplantation into nude mice. (1979). Subject Strain Bibliography 1979. 2465 ...
TY - JOUR. T1 - 1H-NMR relaxation times and water compartmentalization in experimental tumor models. AU - Braunschweiger, P. G.. AU - Schiffer, L. M.. AU - Furmanski, P.. PY - 1986. Y1 - 1986. N2 - The present studies were conduced with RIF-1, M5076 and Panc02 subcutaneous tumor models to assess the relationship between tissue-free water compartmentalization and observed tissue T1 and T2 changes at 10 MHz. Observed T1 was shown to correlate directly with total extracellular water and interstitial water volumes. T1 and T2 were also inversely related to intracellular water volumes. T1 and T2 decreases after dexamethasone treatment were, however, most closely correlated with changes in tumor extracellular water and not changes in cell or total water volumes. Studies to assess Gd-DTPA-dimeg dose dependent T1 and T2 modification in model serum protein solutions indicated that although the Gd concentration that reduced T2 by 50% was about 2.5 fold greater than that required to reduce T1 equally, the ...
Inoculation of mice from appropriate crosses with two strain A tumours and one dba (subline 2) tumour showed close linkage of such a gene with the locus for fused. With the A strain it was shown that the gene was identical with that for antigen II present in the erythrocytes. The gene is therefore labelled $H_{2}$. Of sixty-nine backcross mice tested, both serologically and by tumour inoculation, sixty-five gave concordant results, four discordant results. In general, it appears that serological tests are preferable to tumour inoculation in the identification of genotypes. On serological grounds it is suggested that the dba gene is an allele of the above and should be called $H_{2}{}^{d}$. It is possible that there is a long series of alleles at this locus. The indicated genotype of the strains used is as follows: $A,H_{2}H_{2}$; $dba,H_{2}{}^{d}H_{2}{}^{d}$; CBA, C57 and $P,h_{2}h_{2}$; $CA,Fu$ $h_{2}/fu$ $h_{2}$. Further tests may show differences in the $h_{2}$ allele in the last four ...
A test that detects changing levels of tumour fragments in the blood may be an easy, non-invasive and quick way to predict who will benefit from...
A new cancer therapy, called checkpoint blockade, has had some striking successes, but unfortunately it hasnt shown potential for treating the most lethal tumors. Now scientists are testing a way to spur checkpoint blockade into more potent action using nanoparticles.
TY - JOUR. T1 - Orthotopic transplantation of histologically intact clinical specimens of stomach cancer to nude mice. T2 - Correlation of metastatic sites in mouse and individual patient donors. AU - Furukawa, Toshiharu. AU - Kubota, Tetsuro. AU - Watanabe, Masahiko. AU - Kitajima, Masaki. AU - Hoffman, Robert M.. PY - 1993/2/20. Y1 - 1993/2/20. N2 - Fresh surgical specimens derived from 36 patients with advanced stomach cancer were orthotopically transplanted in nude mice using histologically intact tissue. Twenty of 36 patient tumors gave rise to locally growing tumors in the mice. All 20 patients whose stomach tumors resulted in local growth in the nude mice had clinical lymph‐node involvement, whereas 8 of the other 16 patients whose tumors were rejected had lymph‐node involvement. There was a statistical correlation(p ,0.01) between local tumor growth in nude mice and clinical lymph‐node involvement. Of the 20 cases resulting in local growth in the nude mice, 5 had clinical liver ...
Purpose: Cultured tumor fragments from melanoma metastases have been used as a source of tumor-infiltrating lymphocytes (TIL) for adoptive cell therapy. The expansion of tumor-reactive CD8+ T cells with IL-2 in these early cultures is critical in generating clinically active TIL infusion products, with a population of activated 4-1BB CD8+ T cells recently found to constitute the majority of tumor-specific T cells. Experimental Design:We used an agonistic anti-4-1BB antibody added during the initial tumor fragment cultures to provide in situ 4-1BB co-stimulation. Results: Addition of an agonistic anti-4-1BB antibody could activate 4-1BB signaling within early cultured tumor fragments and accelerated the rate of memory CD8+ TIL outgrowth that were highly enriched for melanoma antigen specificity. This was associated with NFkappaB activation and the induction of T-cell survival and memory genes, as well as enhanced IL-2 responsiveness, in the CD8+ T cells in the fragments and emerging from the ...
BioAssay record AID 710427 submitted by ChEMBL: Binding affinity to TLR2 in human SU.86.86 cells xenografted in Harlan athymic nude mouse tumor assessed as increase in fluorescence at 100 nmol/kg, iv measured up to 24 hrs.
Apffel, C A. and Peters, J H., Successful heterotransplantation of l1210 mouse leukosis into un- treated adult hamsters. Abstr. (1968). Subject Strain Bibliography 1968. 45 ...
Figure 4. Treg lineage instability removes intratumor immune suppression. A and B, experiment schematic: tumors were isolated and dissociated, and 10,000 live tumor cells were then embedded along with all tumor-infiltrating cells (∼3-5 times tumor cell counts) in collagen-fibrin gel together with or without CTLs as described in Materials and Methods. After 24, 48, and 72 hours, gels were lysed and viable cells were cultured in a colony-forming assay. No killing would appear with 100+ colonies, and killing would show very few colonies. A, graphs show number of viable tumor cells recovered at indicated time points for IgG (left) and DTA-1 (middle) for total tumors alone (blue line) or with activated OT-1 T cells (red line). Right, rate of B16 cell killing by OT-1 CTL (killing constant k, as calculated in Materiala and Methods), of IgG (dark gray) and DTA-1 (white) tumors is shown compared with primary tissue culture B16 cells alone (light gray). B, viable tumor cells recovered from cultures of ...
Many cancer cell types, as well as their metastases, express high levels of CD44. Whereas some tumors, such as gliomas, exclusively display CD44s, other neoplasms, including brain metastases, gastrointestinal cancer, pancreatic adenocarcinoma, bladder cancer, uterine cervical cancer, breast cancer and non-Hodgkins lymphomas, additionally and sometimes preferentially express CD44 variants. Hence, CD44, particularly its variants, may be used as diagnostic or prognostic markers of at least some human malignant diseases. Furthermore, it has been demonstrated in animal models that upon transfection with CD44s, or CD44v cDNA, nonmetastatic tumor cells acquire metastatic potential. In addition, injection of reagents interfering with CD44-ligand interaction (e.g. CD44s- or CD44v-specific mAb) inhibit local tumor growth and metastatic spread in murine species. In this context, CD44 may confer a growth advantage on some neoplastic cells, and consequently could be used as a target for cancer therapy. The ...
I recently read with great interest, the opposing viewpoints on Is there enough benefit to justify sequencing all patients tumors?, published in JAMA Oncology (April 14, 2016). From the Yes side: sequencing technology provides invaluable intelligence to diagnose, treat, and defeat cancer (Universal Genomic Testing Needed to Win the War Against Cancer by Razelle Kurzrock, MD, and Vivek Subbiah, MD). From the No side: rigorously tested superiority and outcome data are lacking and the cost to patients is still prohibitive (No Solid Evidence, Only Hollow Argument for Universal Tumor Sequencing by Howard Jack West, MD). Both of these are compelling arguments, in spite of their contradictory nature, that deserve ongoing consideration in the oncology community. What we are increasingly coming to understand is that beyond a relatively small set of driver aberrations, whose testing and treatment are specified in standard treatment guidelines, there are a wealth of other molecular abnormalities in ...
Checkpoint blockade targeting PD-1/PD-L1 has clinical efficacy in a variety of tumor types, and has been shown to function through activation of T cells. However, PD-1 is also expressed on macrophages, prompting Gordon and colleagues to investigate the effects of PD-1 blockade on macrophages in the tumor microenvironment. Fluorescence-activated cell sorting of cells from syngeneic colon cancer models revealed that approximately 50% of tumor-associated macrophages (TAM) expressed surface PD-1. In contrast, no circulating monocytes or splenic macrophages had detectable PD-1 expression. The majority of PD-1+ TAMs exhibited an M2-like surface profile, suggesting a protumor phenotypes, whereas the PD-1− TAMs were often M1-like, indicative of an inflammatory phenotype. The PD-1+ TAM population emerged approximately 2 weeks after tumor engraftment, and PD-1 expression increased over time. Consistent with these findings, TAMs from human colorectal tumors exhibited high but variable expression of PD-1, ...
Maloney began by explaining that CAR-T cells produced from distinct T-cell subsets differ in potency. NSG mice bearing Raji tumors (0.5x10 6tumor cell inoculation; day 0) were treated with human CAR-T cells manufactured from distinct T-cell subsets (on day 7). CAR-T cells produced from CD8 +T CMcells were highly potent ( Sommermeyer et al.2015).. Engineering selected T-cell subsets could enhance potency and allow delivery of the same cell product in all patients, potentially providing more uniform data on dose response and toxicity.. Pre-clinical studies have established that a defined composition of CD8 +T CMderived and CD4 +derived CAR T-cells provides optimal potency.. ...
Our groups cover a broad spectrum of interdisciplinary expertise, from mathematical modeling, cell biology, biochemistry, structural, developmental and stem cell biology to immunology, experimental tumor models and clinical oncology.. We place special emphasis on the translation of scientific findings into the clinics for the development of novel therapies, including drugs, gene and cell therapy approaches, and collaborate closely with clinically oriented groups at the Charité - Universitätsmedizin Berlin.. ...
Murine leukemia L1210 has been treated with cyclophosphamide and 4 sublines have been developed from the tumor cells surviving drug therapy. Biologic studies have demonstrated a marked alteration of virulence compared to the parent tumor and striking cytogenetic modifications have been found to exist. Serial examinations over an interval of 22 weekly transplant generations have demonstrated a biologic and cytogenetic instability characterized by, generally, a tendency for return toward control values.. ...
Carcinoembryonic antigen (CEA) was purified from GW-39 human tumor xenografts in hamsters by immunoaffinity chromatography. Binding of the antigen to immobilized monoclonal antibody provided a high degree of purification of CEA in a single step. A recovery of 79% and a 750-fold purification were obtained. The purified CEA has a molecular size of 180 kilodaltons, an isoelectric point of 4.4, and a specific activity of 0.94. About 73% of the radiolabeled GW-39 CEA reacted with goat anti-CEA serum ...
Original FAG 546238A bearing. BIS 540626AA.J30NF Bearing BIS 540733BA Bearing BIS 540733CA Bearing BIS 540805A Bearing BIS 541019.S3 Bearing BIS 541332A.K158X4 *4 Bearing BIS 541521C Bearing BIS 542186A Bearing BIS 543185A Bearing BIS 543187A Bearing BIS 54322MP Bearing BIS 543307A.K158X12 *12 Bearing BIS 544307D Bearing BIS 544873TVP Bearing BIS 545312A Bearing BIS 545495AD Bearing BIS 546065.C3.L145 Bearing BIS 546238A ...
nude mouse definition: a mouse with an inherited problem that prevents all of them from developing locks also stops them from immunologically rejecting personal cells and tissues; popular in preclinical…
TY - JOUR. T1 - Decreased macrophage‐mediated cytotoxicity in mammary‐tumor‐bearing mice is related to alteration of nitric‐oxide production and/or release. AU - Sotomayor, Eduardo M.. AU - Dinapoli, Michael R.. AU - Calderón, Cesar. AU - Colsky, Arthur. AU - Fu, Yang‐Xin ‐X. AU - Lopez, Diana M.. PY - 1995/3/3. Y1 - 1995/3/3. N2 - Peritoneal‐exudate macrophages (PEM) from mammarytumor‐bearing mice have impaired cytotoxic activity against syngeneic and allogeneic tumor targets. The ability of PEM from normal and tumor‐bearing mice to bind tumor targets was found to be similar in the presence or the absence of surrogate receptors, which enhanced the binding but not the killing of tumor targets by PEM from tumor‐bearing mice, suggesting that other mechanisms are involved in their impaired cytolytic activity. Soluble and membrane‐bound TNF‐α, as well as H2O2, were found in higher amounts in PEM from tumor bearers upon stimulation with LPS, as compared with PEM from normal ...
The ability to generate a large number of tumor-reactive T lymphocytes is the most critical requirement for adoptive immunotherapy. Our laboratory has previously demonstrated that cells from tumor-draining lymph nodes (LNs) are an excellent source of tumor-reactive T lymphocytes. After activation with anti-CD3, these cells readily proliferate in low concentrations of interleukin 2 and acquire effector functions. The adoptive transfer of these cells is capable of mediating the regression of tumors established in the lung as well as in the brain. Here, we analyzed several adhesion molecules on the tumor-draining LN T cells and separated them based on l-selectin expression. The homing receptor l-selectin mediates adhesion to the luminal surface of specialized high endothelial venules, thus regulating lymphocyte recirculation through peripheral LNs. In response to progressive tumor growth, a small population of draining LN T cells down-regulated l-selectin and increased the expression of CD44 and ...
Summary Simian virus 40 (SV40)-transformed cells express the SV40-specific tumour transplantation antigen (TSTA) on the cell surface and the SV40-coded tumour antigen in their nuclei. TSTA is defined by SV40-specific transplantation immunity, whereas T-antigen (T-Ag) can be detected serologically by indirect immunofluorescence. Both antigens, however, are derived from the A gene of SV40. We therefore analysed SV40-transformed cells for the presence of serologically detectable T-Ag-related molecules. Such antigens could not be detected on the surface of living SV40-transformed cells in monolayers. However, after a short formaldehyde fixation it was possible to stain the cell surfaces of SV40-transformed cells with sera from rabbits immunized with purified SDS-denatured T-Ag, but not with sera from hamsters bearing SV40-induced tumours. T-Ag-related antigens could be detected with both types of antisera by applying a more sensitive 125I-protein A assay. The T-Ag specificity of the binding of hamster SV40
It is well understood by oncologists that tumor growth and metastasis depend on changes in the tumor microenvironment or stroma. Stromal changes have been the focus of numerous research publications and have led to insights in both tumor development and promising new avenues for treatment [1-7].. In order to study molecular changes in stroma from tissue samples, it is necessary to separate tumor tissue from stromal tissue. Without this separation we have sample heterogeneity, which is well known to severely limit the conclusions that can be made about the specificity of molecular changes and their biological causes [5, 7-11]. This separation can be difficult in contexts where tumors are small or not well differentiated. For example, in mouse tumor xenograft models, human cancer cells are grown in immune-suppressed mice [12-15]. These models are popular in oncologic research for studying mechanisms of tumor growth and metastasis, as well as drug response. In such studies, secondary tumors (at ...
Background: The reasons why the lungs are preferential metastatic targets for some human cancers are unknown.. Aims: To unravel the mechanism of tumor pneumotropism.. Methods: Several mouse and human tumor cell lines were genotyped for key oncogenes and tumor suppressors. Their potential for spontaneous lung metastasis was assessed by subcutaneous inoculation into receptive host mice. Mutant oncogenes were silenced via shRNA or introduced using relevant expression vectors. Chemokine signaling was studied using microarray, qPCR, ELISA and immunobloting and was abrogated using chemokine receptor-deficient mice.. Results: Spontaneous lung metastasis co-segregated with the presence of NRAS mutations detected in 3 of 11 cell lines studied. The expected frequency of NRAS mutations based on COSMIC (http://cancer.sanger.ac.uk/cosmic/) was tightly correlated (P=0.0000054, R2=0.652) with lung metastasis at necropsy in 3827 patients with various cancers (Disibio, G. et al. Arch Pathol Lab Med ...
A competent and expanding vascular supply is a necessary component of the progressive growth of solid tumors because cells in solid tumors, like normal tissue, must receive oxygen and other nutrients to survive and grow (17) . The connection between oxygen supply and tumor growth was first made in the 1950s by radiobiologists who were aware of oxygen as a radiosensitizer and the fact that hypoxic cells in tumors are resistant to radiation therapy (18) . Histological analyses of human and rodent tumors performed by Thomlinson and Gray (18) were the first studies to suggest that regions of viable cells exist close to tumor blood vessels and that these walls or cords of viable tumor cells correspond in thickness to the distance that oxygen can diffuse (1-2 mm3). The tumor cord model implied that hypoxic cells exist in a state of oxygen and nutrient starvation at the limits of the diffusion range of oxygen, and it was hypothesized that tumor cells could proliferate and grow only if they were close ...
TY - JOUR. T1 - Abdominal-wall tumor implantation after laparoscopy for malignant conditions. AU - Childers, Joel M.. AU - Aqua, Keith A.. AU - Surwit, Earl A.. AU - Hallum, Alton V.. AU - Hatch, Kenneth D.. PY - 1994/11. Y1 - 1994/11. N2 - Objective: To determine the incidence of abdominal-wall tumor implantation after laparoscopic procedures in patients with known malignancies. Methods: We reviewed 557 laparoscopic procedures performed by the Gynecologic Oncology Service between November 1990 and February 1994. In 105 procedures, malignancy was documented cytologically or histologically, 88 with intraperitoneal disease and 17 with retroperitoneal disease. Ovarian cancer represented 80% (70 of 88) of the procedures with intraperitoneal malignancy, and the remaining cases consisted of carcinoma of the fallopian tube (two), endometrium (11), cervix (one), breast (three), and stomach (one). Histologically, ovarian carcinomas ranged from low malignant potential to poorly differentiated. Among 88 ...
Gd-albumin is efficiently accumulated in SCC transplants. MRI with low loaded Gd-albumin may offer relevant opportunities for recognizing tumors sensitive to a therapy with cyostic drug-labeled albumins.
Animal models for human tumor xenografts are used for the study of biology and treatment of human cancer. The aim of this study was to develop a model for long-term tumor observations with the...
Note: This cell line was derived from a 4th passage nude mouse xenograft of tumor fragments obtained from a patient prior to therapy. This cell line is a pseudodiploid human cell line an and has a high concentration of receptors for EGF. This cell line has lost both chromosomes 8 and 11 while SNU-C2A has lost only chromosome 11. Penicillin-streptomycin were added to culture media (final concentration, 100 U/mL ...
PhD Project - Exploring the similarities between neointimal formation after vascular injury and tumour growth at University of Bristol, listed on FindAPhD.com
Cell-line tumor. Huh-7-GFP cells (2×106) in 0.1 ml phosphate-buffered saline (PBS) were initially subcutaneously injected in the shoulder of nude mice. Resulting tumors were harvested and sectioned into small pieces for sutureless SOI to the liver.. Patient-derived tumor. A colon-cancer liver metastasis from a human patient was previously surgically obtained under standard sterile conditions at the UCSD Thornton hospital under UCSD IRB protocol 140046. Informed patient consent to utilize the tumor tissue for research was obtained prior to surgical resection (Figure 1A). Fresh tumor fragments were subcutaneously implanted in nude mice (Figure 1B). Once tumor growth was established subcutaneously, tumors were harvested and sectioned into small pieces for sutureless SOI to the liver (Figure 1C).. Sutureless SOI to the liver. Nude mice (n=10) were injected intra-muscularly with a ketamine solution (0.02 mL) for anesthesia prior to all procedures. The entire abdomen was sterilized with a 70% ethanol ...
OUTLINE: Previously collected breast tumor fragments are implanted into the renal capsule site of SCID mouse hosts (mouse with severe combined immune deficiency) to establish metastatic spread patterns, and both histologic and molecular tumor characteristics.. Patients medical charts are reviewed to obtain relevant information, including general demographics, smoking and alcohol use, as well as outcome data such as survival and response to treatment. ...
OUTLINE: Previously collected breast tumor fragments are implanted into the renal capsule site of SCID mouse hosts (mouse with severe combined immune deficiency) to establish metastatic spread patterns, and both histologic and molecular tumor characteristics.. Patients medical charts are reviewed to obtain relevant information, including general demographics, smoking and alcohol use, as well as outcome data such as survival and response to treatment. ...
Fingerprint Dive into the research topics of Enhanced metastatic potential of tumor cells harvested from spontaneous metastases of heterogeneous murine tumors. Together they form a unique fingerprint. ...
Abstract. Concomitant tumor resistance (CR) is a phenomenon in which a tumor-bearing host is resistant to the growth of secondary tumor implants and metastasis. While former studies have indicated that T-cell dependent processes mediate CR in hosts bearing immunogenic small tumors, the most universal manifestation of CR induced by immunogenic and non-immunogenic large tumors had been associated with an antitumor serum factor that remained an enigma for many years. In a recent paper, we identified that elusive factor(s) as an equi-molar mixture of meta-tyrosine and ortho-tyrosine, two isomers of tyrosine that are not present in normal proteins and that proved to be responsible for 90% and 10%, respectively, of the total serum anti-tumor activity. In this work, we have extended our previous findings demonstrating that a periodic intravenous administration of meta-tyrosine induced a dramatic reduction of lung and hepatic metastases generated in mice bearing two different metastatic murine tumors ...
Includes syngeneic models, human tumor xenograft models, orthotopic models, metastatic models, transgenic models, and gene knockout models Provides
Time-lapse movie of a human tumor fragment grown in Matrigel that was freed and reembedded in collagen I. Images collected every 15 minutes and bar i...
Annibale Carracci Fine Art Open Edition Gicl e:A Male Nude Seated with His Back Turned Artist: Annibale Carracci Title: A Male Nude Seated with His Back Turned Size: 30 x 19.9 Edition: Open Edition Medium: Fine Art Giclee on Paper ...
A newly funded TFRI dream team plans to tackle the most lethal and aggressive brain tumour that occurs in adults by focusing not on the original tumour, but on the relapsed cancer. &ldqu... Read More ...
Original KOYO 51280 bearing. INA GG 51280 Bearing INA B66 Bearing INA NK73/35 Bearing INA NK73/35 Bearing INA RUS 26126 Gr 4 Bearing INA PR14089.G...
I will introduce some KOYO bearings to you in this article,if you are in need of any of the below listed bearings,please send your valued inquiry to us.At the moment .... ...
Concomitant immunity is a phenomenon in which a tumour-bearing host is resistant to the growth of an implanted secondary tumour. Metastases are considered to be secondary tumours that develop spontaneously during primary tumour growth, suggesting the involvement of concomitant immunity in controlling the rise of metastases. It has been demonstrated that B-1 cells, a subset of B-lymphocytes found predominantly in pleural and peritoneal cavities, not only increase the metastatic development of murine melanoma B16F10, but also are capable of differentiating into mononuclear phagocytes, modulating inflammatory responses in wound healing, in oral tolerance and in Paracoccidiose brasiliensis infections. Here, we studied B-1 cells participation in concomitant immunity during Ehrlich tumour progression. Our results show that B-1 cells obtained from BALB/c mice previously injected with Ehrlich tumour in the footpad were able to protect BALB/c and BALB/Xid mice against Ehrlich tumour challenge. in ...
TY - JOUR. T1 - Clodronate-Liposome Mediated Macrophage Depletion Abrogates Multiple Myeloma Tumor Establishment In Vivo. AU - Opperman, Khatora S.. AU - Vandyke, Kate. AU - Clark, Kimberley C.. AU - Coulter, Elizabeth A.. AU - Hewett, Duncan R.. AU - Mrozik, Krzysztof M.. AU - Schwarz, Nisha. AU - Evdokiou, Andreas. AU - Croucher, Peter I.. AU - Psaltis, Peter. AU - Noll, Jacqueline E.. AU - Zannettino, Andrew. PY - 2019/8/1. Y1 - 2019/8/1. N2 - Multiple myeloma is a fatal plasma cell malignancy that is reliant on the bone marrow microenvironment. The bone marrow is comprised of numerous cells of mesenchymal and hemopoietic origin. Of these, macrophages have been implicated to play a role in myeloma disease progression, angiogenesis, and drug resistance; however, the role of macrophages in myeloma disease establishment remains unknown. In this study, the antimyeloma efficacy of clodronate-liposome treatment, which globally and transiently depletes macrophages, was evaluated in the ...
Looking for online definition of Athymic nude mouse in the Medical Dictionary? Athymic nude mouse explanation free. What is Athymic nude mouse? Meaning of Athymic nude mouse medical term. What does Athymic nude mouse mean?
Purpose: The avascular cornea is predestined to study neovascular responses. First experiences with this model date back to 1972, when Gimbrone et al heterotopically implanted tumor fragments in rabbit corneal pockets. Different assays in rabbit, rat, and mouse corneas have since been published including placement of (anti-)angiogenic growth factor releasing pellets or proangiogenic corneal sutures. Using murine corneas is surgically more intricate but advantageous due to the well-defined genetic background and availability of genetically modified animals. In mice, so far tumor-associated angiogenesis has been studied by inserting pre-grown tumor fragments into corneal pockets. Here we describe an alternative approach, where a suspension of cultured tumor cells is directly injected into the corneal stroma.. Methods: One µl of B16F10 melanoma cells suspended in PBS (100.000 cells/µl) and pre-stained with FITC+ CellTracker Green was injected into the paracentral corneal stroma of C57Bl/6 mice ...
TY - JOUR. T1 - Comparison of L bleomycin prepared by two methods. T2 - Stability and pharmacokinetics in tumor bearing mice. AU - Krohn, K. A.. AU - Meyers, J.. AU - Denardo, Gerald L. PY - 1977. Y1 - 1977. UR - http://www.scopus.com/inward/record.url?scp=0017623084&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=0017623084&partnerID=8YFLogxK. M3 - Article. C2 - 63131. AN - SCOPUS:0017623084. VL - 122. SP - 179. EP - 182. JO - Radiology. JF - Radiology. SN - 0033-8419. IS - 1. ER - ...
TY - JOUR. T1 - Protective immunity induced by B7.1+IL-12 transfected tumor cells is abrogated by tumor growth in an immune privileged site. AU - Chen, P. W.. AU - Uno, T.. AU - Geer, D. G.. AU - Podack, E. R.. AU - Ksander, B. R.. PY - 1996/12/1. Y1 - 1996/12/1. N2 - Mice immunized with B7.1+IL-12 transfected tumor cells possess systemic anti-tumor immunity that protects mice from a second subcutaneous tumor challenge of untransfected cells. This study determines if these immunized mice are protected from a second tumor challenge delivered to an immunologically privileged site. Our previous results indicated that tumors growing within the immunologically privileged anterior chamber of the eye (AC) of naive mice induce systemic T cell tolerance. In these experiments we determined if tolerance could be imposed after mice were previously sensitized. DBA/2 mice were given a subcutaneous immunization with 1 × 106 P815 B7.1+IL-12 cells. One month later, mice received a second tumor challenge of ...
A two-stage modification of the leucocyte adherence inhibition (LAI) test is described, which quantitates cell-mediated immunity (CMI) in vitro with 0.5-ml samples of blood from mice exposed to methylcholanthrene-induced tumors. The total blood cells are washed and incubated for 30 min with tumor antigen, then centrifuged, and the supernatant assayed in the LAI test with normal peritoneal cells. The first stage of the reaction depends on the rapid formation of a soluble mediator which appears to be a lymphokine. By this method, the daily changes in specific CMI were followed in individual mice after syngeneic tumor transplantation ...
This is one of 14 colorectal carcinoma cell lines derived by J.G. Park and associates during the years 1982 through 1985. The line was obtained from a fourth passage nude mouse xenograft of tumor fragments obtained from a patient prior to therapy (see also ATCC CCL-250.1 which was derived from the third nude mouse passage).
In control arm, the tumor grew the fastest within the first couple weeks. As the tumor enlarged, we noticed a decline in growth rate of these tumors. In the control arm, the tumor growth rate was significantly higher in the first 15 days compared to the second 15 days. The tumor volume doubling time changed from 103 h in the first 15 days to 144 h in the second 15 days (P , 0.01). However, in the 2 mg T and 5 mg T arms, the opposite results were found. The data demonstrated that in 2 mg T and 5 mg T arms, the tumor growth rate was significantly lower in the first 15 days compared to the second 15 days, (184 h vs 133 h in 2 mg T arm, P , 0.05, 206 h vs 140 h in 5 mg T arm, P , 0.01). When comparing the growth rates of the control arm and the 2 mg T and 5 mg T arms in the first 15 days, the growth rates were much higher in the control arm (P , 0.01). However, in the second 15 days there was no significant difference in tumor growth rates in the control arm, 2 mg T arm, and 5 mg T arms (Fig. 4). ...
Tumors adapt to an unfavorable microenvironment by controlling the balance between cell proliferation and cell motility, but the regulators of this process are largely unknown. Here, we show that an alternatively spliced isoform of syntaphilin (SNPH), a cytoskeletal regulator of mitochondrial movements in neurons, is directed to mitochondria of tumor cells. Mitochondrial SNPH buffers oxidative stress and maintains complex II-dependent bioenergetics, sustaining local tumor growth while restricting mitochondrial redistribution to the cortical cytoskeleton and tumor cell motility. Conversely, introduction of stress stimuli to the microenvironment, including hypoxia, acutely lowered SNPH levels, resulting in bioenergetics defects and increased superoxide production. In turn, this suppressed tumor cell proliferation but increased tumor cell invasion via greater mitochondrial trafficking to the cortical cytoskeleton. Loss of SNPH or expression of an SNPH mutant lacking the mitochondrial localization ...
Tumors adapt to an unfavorable microenvironment by controlling the balance between cell proliferation and cell motility, but the regulators of this process are largely unknown. Here, we show that an alternatively spliced isoform of syntaphilin (SNPH), a cytoskeletal regulator of mitochondrial movements in neurons, is directed to mitochondria of tumor cells. Mitochondrial SNPH buffers oxidative stress and maintains complex II-dependent bioenergetics, sustaining local tumor growth while restricting mitochondrial redistribution to the cortical cytoskeleton and tumor cell motility. Conversely, introduction of stress stimuli to the microenvironment, including hypoxia, acutely lowered SNPH levels, resulting in bioenergetics defects and increased superoxide production. In turn, this suppressed tumor cell proliferation but increased tumor cell invasion via greater mitochondrial trafficking to the cortical cytoskeleton. Loss of SNPH or expression of an SNPH mutant lacking the mitochondrial localization ...
Adoptive cell transfer of tumor infiltrating lymphocytes has shown clinical efficacy in the treatment of melanoma and is now also being explored in other tumor types. Generation of sufficient numbers of effector T cells requires extensive ex vivo expansion, often at the cost of T cell differentiation and potency. For the past 20 years, IL-2 has been the key cytokine applied in the expansion of TIL for ACT. However, the use of IL-2 has also led to collateral expansion of regulatory T cells (Tregs) and progressive T cell differentiation, factors known to limit in vivo persistence and activity of transferred TIL. The use of alternative T cell growth factors is therefore warranted. Here, we have compared the effects of IL-2, -15 and −21 cytokines on the expansion and activation of TIL from single-cell suspensions of non-small cell lung cancer, ovarian cancer and melanoma. We applied the K562-based artificial APC (aAPC) platform for the direct and rapid expansion of tumor infiltrating lymphocytes isolated
Consistent with previous observations, c-Met Inhibitors staining exposed substantial regions of hemorrhagic necrosis devoid of CD31 staining along with viable tumor cells and CD31 blood vessels in the tumor rim. Interestingly, CD31 immunostained sections of orthotopic MCA tumors showed a really selective vascular response to DMXAA with intact vasculature noticeable in the neighboring muscle tissue.. Evaluation of R1 values of muscle tissue had been consistent with this observation and showed no statistically important big difference amongst handle and treatment method groups. Ultimately, we determined if the differential vascular response to DMXAA among ectopic and orthotopic MCA tumors correlated with intratumoral levels of TNF, a principal cytokine concerned in antivascular activity of DMXAA. Differences in intratumoral VEGF ranges have been also analyzed. As proven in Fig. 5A, untreated handle MCA tumors established at ectopic and orthotopic tissue sites showed very reduced amounts of TNF, ...
LY294002 price The sole reproducible distinction among wild variety and NG2 null specimens was the lowered num ber of lesions obvious at early time points in the absence of NG2, reinforcing the conclusions acquired from your total mount staining. Progression of transplanted mammary tumors Donor MMTV PyMT tumor fragments were transplanted into mammary extra fat pad web sites in 4 month old female wild sort and NG2 null mice that didnt carry the MMTV PyMT transgene. In wild style mice, 50% of transplantation web-sites had detectable tumors at 40 days post implantation. In NG2 null mice, the time for 50% incidence was extended to 80 days. Comparable outcomes had been obtained in a 2nd experiment using two month previous recipient females. These changes in tumor latency concerning wild kind and NG2 null mice therefore mimic the differences in latency seen with spontaneous mammary tumor advancement. Progression of mammary tumors from cell lines The Py230 and Py8119 cell lines were the two derived ...
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.. ...
www.MOLUNA.de Systems Biology of Tumor Dormancy [4197128] - This volume is based on the Workshop on Systems Biology of Tumor Dormancy meeting, held July 25th to July 28th, 2011. The first annual CCSB workshop brought together biologists, clinicians, mathematicians, and computer scientists to discuss various aspects of tumor dormancy and develop novel mathematical/computational models with the keynote speakers.
MSpace maintenance is scheduled to be performed between 9:00AM and 12:00PM CST on Thursday Jan 23, 2020. Access will be unavailable intermittently during that time. Please plan your submissions accordingly. Any in-progress submissions should be saved before the maintenance period.. ...
The majority of in vivo models of metastasis determine the effect of experimental conditions (usually via knock-out mice) by relying on the end point of secondary tumor formation at a distal site (14). However, the steps occurring between tumor cell injection and metastatic tumor formation are effectively shrouded in these models (15). Despite advances in imaging to monitor these processes, a crucial step of metastasis-the invasion and colonization of cancer cells upon extravasation-remains an elusive target. This study describes a three-dimensional culture system developed to model this phase in vitro and establishes the efficacy of this novel system by demonstrating that cells from disparate phases of melanoma invade the matrix in a manner proportional to their known metastatic capabilities. Specifically, the highly metastatic C8161.9 stayed true to its documented in vivo behavior (21), ferociously staking claim to much of the surrounding matrix (Fig. 1A-C). The sporadically metastatic M14 ...
Cancer is a class of diseases in which a group of cells displays uncontrolled growth and invasion that destroys adjacent tissues, and sometimes send metastasis to other locations in the body. When one is interested in cancer research, mice will be the preferred animal. Murine models of cancer include transplantable models, spontaneous and autochthonous models, human tumor xenografts, orthotopic models, models of metastasis and transgenic tumor models.
PDT in tumor-bearing mice. (a) 4T1 cells were injected subcutaneously in two separate locations on the back of BALB/c mice. After tumors were established (marke
A xenograft is cells or sections of tissue that are removed from one species and grafted onto another species. The main reason for...
如新NU酷提供全面的NUSKIN如新产品图、NUSKIN如新产品视频、美容仪视频、护肤品图片等信息介费。更多关于NUSKIN如新产品图、NUSKIN如新产品视频信息就在NUSKIN如新官网!
蘇松濤報導】 據2021年Pinterest Predicts最新報告,現代人對社群修圖美學逐漸厭倦,反思生活中的真實性與對建構肌膚健康的基本要求。全球第一美容儀霸主Nu.... ...
"The association of Epstein-Barr virus with smooth-muscle tumors occurring after organ transplantation". N. Engl. J. Med. 332 (1 ... ICD-10 classifies neoplasms into four main groups: benign neoplasms, in situ neoplasms, malignant neoplasms, and neoplasms of ... The term 'neoplasm' is a synonym of "tumor". 'Neoplasia' denotes the process of the formation of neoplasms/tumors, the process ... "II Neoplasms". World Health Organization. Retrieved 19 June 2014.. *^ a b Abrams, Gerald. "Neoplasia I". Retrieved 23 January ...
Reparative surgery 120.6-129.8.............................Transplantation of organs, tissues, etc. 130 ... Neoplasms. Tumors. Oncology 680-688...................................Diseases of the locomotor system (Surgical treatment) 701 ... Neoplasms. Tumors. Oncology Including cancer and carcinogens 306-320.5................................Tuberculosis 321-571 ...
EMH in the lymph nodes is usually associated with underlying hematopoietic neoplasms. Myeloproliferative neoplasms (MPNs) tend ... This includes transplantation, hepatic tumors, hepatic disorders, or sepsis. Hepatoblastoma, adenomas and hepatocellular ... para-nasal sinuses and numerous types of benign/malignant neoplasms. The most common sites of EMH associated with neoplastic ... "Pulmonary extramedullary hematopoiesis in patients with myelofibrosis undergoing allogeneic stem cell transplantation". ...
Robert J. Soiffer (17 November 2008). Hematopoietic Stem Cell Transplantation. Springer. ISBN 978-1-934115-05-3. Retrieved 23 ... Cazzola M, Malcovati L, Invernizzi R (2011). "Myelodysplastic/myeloproliferative neoplasms". Hematology Am Soc Hematol Educ ... "Myelodysplastic/myeloproliferative neoplasms". Am. J. Clin. Pathol. 132 (2): 281-9. doi:10.1309/AJCPJ71PTVIKGEVT. PMID 19605822 ... classification of the myeloid neoplasms". Blood. 100 (7): 2292-302. doi:10.1182/blood-2002-04-1199. PMID 12239137. Vardiman J, ...
Hematopoietic stem cell Hematopoietic stem cell transplantation Hematology Myelodysplastic syndrome Myeloproliferative neoplasm ... It has been shown that patients with CHIP who receive autologous stem cell transplantation (ASCT) as part of their treatment ... The poorer prognosis for these patients is due to both an increase in subsequent therapy-related myeloid neoplasms and ... "Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma". Journal of ...
He followed several alternative treatments, such as high vitamin C doses or neoplasm treatment at the Burzynski Clinic in ... Finally, he underwent conventional treatments of chemotherapy and bone marrow transplantation. He was under quarantine in his ...
... lymphoid neoplasms, or features of both types of neoplasms. Most commonly, the present with features of myeloid neoplasms with ... This patient achieved a complete hematological response and was then given a hematopoietic stem cell transplantation. The ... Like the latter neoplasm, hematologic neoplasms cause by ETV6-JAK2 and BCR-JAK2 are aggressive and progress rapidly. Too few ... A classic example of such a disease is chronic myelogenous leukemia, a neoplasm commonly caused by a mutation that creates the ...
... myeloproliferative neoplasms, mast cell diseases and stem cell transplantation. In the past, Turner was the medical director of ...
Comparison of Neoplasms in Six Sources of Rats *^ Diamond JM (January 2006). Collapse: How Societies Choose to Fail or Succeed ... Current research applications include transplantation research, induced arthritis and inflammation, experimental allergic ... A 1972 study compared neoplasms in Sprague Dawley rats from six different commercial suppliers and found highly significant ... they can suffer from high incidences of neoplasms, with the rat's lifespan mainly determined by this. The most common are ...
Vega F, Medeiros LJ, Bueso-Ramos CE, Arboleda P, Miranda RN (2015). "Hematolymphoid neoplasms associated with rearrangements of ... the aggressive chemotherapy and/or bone marrow transplantation used to treat aggressive leukemia may be required. While the ... Reiter A, Gotlib J (2017). "Myeloid neoplasms with eosinophilia". Blood. 129 (6): 704-714. doi:10.1182/blood-2016-10-695973. ... a type of myeloproliferative neoplasm/myeloblastic leukemia not distinguished by eosinophilia; or c) T-lymphoblastic leukemia/ ...
... renal and cardiac transplantation, carcinoma of the head or neck, and other neoplasms (e.g., lung cancer, lymphoma, and ...
Topics included meningoencephalitis, cerebral atrophy, facial nerve paralysis, fibrous tissue neoplasm, lipoma, the anatomy of ... the endothelium, corneal transplantation, skin grafting, dental implants, hysterectomy, various types of cysts and "rare tumors ...
Most hepatectomies are performed for the treatment of hepatic neoplasms, both benign or malignant. Benign neoplasms include ... Partial hepatectomies are also performed to remove a portion of a liver from a live donor for transplantation. A hepatectomy is ... The most common malignant neoplasms (cancers) of the liver are metastases; those arising from colorectal cancer are among the ... typically cancer centres and transplantation centres).[citation needed] For optimal results, combination treatment with ...
It can also involve bone marrow transplantation. Information on prognosis is limited by the rarity of the condition. Prognosis ... myeloproliferative neoplasms, chemotherapy for other cancers or exposure to toxins were defined as secondary AEL. These cases ... and in patients who had previously received chemotherapy for the treatment of a different neoplasm. Acute erythroid leukemia is ...
The incidence of MTS in patients with sebaceous neoplasms as high as 14 to 50%. Besides mutations in mismatch repair genes, Wnt ... there is evidence to suggest that solid organ transplantation may increase the risk of SGc up to 90 times. Others have observed ... SGc accounts for approximately 0.7% of all skin cancers and 0.2 to 4.6% of all malignant cutaneous neoplasms. Notable risk ... MTS is an autosomal dominant cancer syndrome characterized by multiple sebaceous and visceral neoplasms, the most common being ...
"The association of Epstein-Barr virus with smooth-muscle tumors occurring after organ transplantation". N. Engl. J. Med. 332 (1 ... ICD-10 classifies neoplasms into four main groups: benign neoplasms, in situ neoplasms, malignant neoplasms, and neoplasms of ... The term "neoplasm" is a synonym of "tumor". "Neoplasia" denotes the process of the formation of neoplasms/tumors, the process ... p. Neoplasm. ISBN 978-0781733908. "II Neoplasms". International Statistical Classification of Diseases and Related Health ...
Hematopoietic stem cell transplantation can be a curative treatment for a small group of patients, however MPN treatment is ... In MPNs, the neoplasm (abnormal growth) starts out as benign and can later become malignant. As of 2016, the World Health ... Myeloproliferative neoplasms (MPNs) are a group of rare blood cancers in which excess red blood cells, white blood cells or ... "What are Myeloproliferative Neoplasms (MPNs)?". Barbui T, Thiele J, Gisslinger H, Kvasnicka HM, Vannucchi AM, Guglielmelli P, ...
Allogeneic hematopoietic stem cell transplantation should be considered in fit patients with suitable available donor, as long ... Vega F, Medeiros LJ, Bueso-Ramos CE, Arboleda P, Miranda RN (2015). "Hematolymphoid neoplasms associated with rearrangements of ... July 2008). "Allogeneic Hematopoietic Stem-Cell Transplantation for Myeloid Sarcoma: A Retrospective Study From the SFGM-TC". J ... and related neoplasms" those with specific cytogenetic abnormalities (e.g. t(8;21) or inv(16)) those whose myeloblasts express ...
"Histology of Some Neoplasms and Non-Neo-plastic Lesions Found in Wild Mice Maintained Under Laboratory Conditions". JNCI: ... "Transplantation of Hepatomas in Mice1". JNCI: Journal of the National Cancer Institute. April 1955. doi:10.1093/jnci/15. ... "Histology of Some Neoplasms and Non-Neo-plastic Lesions Found in Wild Mice Maintained Under Laboratory Conditions" (1963), " ... "Transplantation of Hepatomas in Mice" (1955), "Morphology of Mammary Tumors in Mice" (1958), "Studies of the Mammary-Tumor ...
Further studies may indicate that this recent cancer chemotherapy regimen plus allogenic bone marrow transplantation in cases ... Vardiman JW, Harris NL, Brunning RD (2002). "The World Health Organization (WHO) classification of the myeloid neoplasms". ... of cases human stem cell transplantation, the probability of overall 4 year survival rate, probability of 4 year event-free ... allogenic rather than autologous stem cell bone marrow transplantation should be considered in non-DS-AMKL cases that have ...
Liver Transplantation Chapter 339: Diseases of the Gallbladder and Bile Ducts Section 4: Disorders of the Pancreas Chapter 340 ... Neoplasms of the Lung Chapter 75: Breast Cancer Chapter 76: Upper Gastrointestinal Tract Cancers Chapter 77: Lower ... Lung Transplantation Part 8: Critical Care Medicine Section 1: Respiratory Critical Care Chapter 293: Approach to the Patient ... Transplantation in the Treatment of Renal Failure Chapter 308: Glomerular Diseases Chapter 309: Polycystic Kidney Disease and ...
Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma. N Engl J Med. 2017 Sep 28;377(13):1250-1260. ... The 2016 revision of the World Health Organization (WHO) classification of lymphoid neoplasms. Blood. 2016 19;127(20):2375-90. ...
After xenogeneic transplantation Sertoli cells were able to proliferate. Sertoli cells are called so because of their eponym ... Sertoli-Leydig cell tumour is part of the sex cord-stromal tumour group of ovarian neoplasms. These tumors produce both sertoli ... By treating spontaneously diabetic and obese mice with the transplantation of microencapsulated Sertoli cells in the ... "Germ cell transplantation as a potential biotechnological approach to fish reproduction". Fish Physiology and Biochemistry. 39 ...
An experimental procedure to treat type 1 diabetes is the transplantation of pancreatic islet cells from a donor into the ... "Solid pseudopapillary neoplasm of the pancreas: a single institution experience of 14 cases". HPB. 8 (2): 148-50. doi:10.1080/ ... Lakey, JR; Burridge, PW; Shapiro, AM (September 2003). "Technical aspects of islet preparation and transplantation". Transplant ...
Comparison of Neoplasms in Six Sources of Rats Diamond JM (January 2006). Collapse: How Societies Choose to Fail or Succeed. ... Current research applications include transplantation research, induced arthritis and inflammation, experimental allergic ... The Lewis rat suffers from several spontaneous pathologies: first, they can suffer from high incidences of neoplasms, with the ... Play media A 1972 study compared neoplasms in Sprague Dawley rats from six different commercial suppliers and found highly ...
"Expertscape: Pancreatic Neoplasms, November 2018". expertscape.com. November 2018. Retrieved 2018-11-26. "Video: Interview with ... "Director of the Clinic for General, Visceral and Transplantation Surgery". Heidelberg surgery hospital. Retrieved 22 March 2012 ... Diseases of the Pancreas: Acute Pancreatitis, Chronic Pancreatitis, Neoplasms of the Pancreas. Karger 2004, ISBN 3-8055-7613-7 ... Visceral and Transplantation Surgery at Heidelberg University Hospital. Since 2003 he is managing medical director of the ...
One patient with ETV6-FLT3-related myeloid/lymphoid neoplasm obtained a short term remission on sunitinib and following relapse ... lymphoblastic leukemia with 2 among 3 family members moving rather quickly from chemotherapy to bone marrow transplantation and ... Reiter A, Gotlib J (February 2017). "Myeloid neoplasms with eosinophilia". Blood. 129 (6): 704-714. doi:10.1182/blood-2016-10- ... myeloproliferative neoplasm (MPN), and acute myeloid leukemia (AML). (The presence of ETV6 gene mutations in myelodysplastic ...
"Biology of Blood and Marrow Transplantation. 15 (12): 1628-33. PMC 2861656 . PMID 19896087. doi:10.1016/j.bbmt.2009.07.004.. ... Secondary neoplasm[edit]. Development of secondary neoplasia after successful chemotherapy or radiotherapy treatment can occur ... In chemotherapy as a conditioning regimen in hematopoietic stem cell transplantation, a study of patients conditioned with ... The most common secondary neoplasm is secondary acute myeloid leukemia, which develops primarily after treatment with ...
STEWART, SE; EDDY, BE; BORGESE, N (June 1958). "Neoplasms in mice inoculated with a tumor agent carried in tissue culture". ... Ramqvist, T; Dalianis, T (August 2009). "Murine polyomavirus tumour specific transplantation antigens and viral persistence in ...
ISBN 0-7020-2606-9. Huete-Garin, A.; S.S. Sagel (2005). "Chapter 6: "Mediastinum", Thymic Neoplasm". In J.K.T. Lee; S.S. Sagel ... The newly formed organ resembled a normal thymus histologically and molecularly, and upon transplantation it was able to ...
Chemotherapy, stem cell transplantation, radiation therapy, targeted therapy[1]. Prognosis. Children: 90% five-year survival ... "The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia". Blood. 127 (20): ... Chemotherapies or stem cell transplantations may require a platelet transfusion to prevent bleeding.[58][59] Moreover, patients ... Stem cell transplantation may be used if the disease recurs following standard treatment.[2] Additional treatments such as ...
The one known curative treatment is allogeneic stem cell transplantation, but this approach involves significant risks.[15] ... In 2016, the WHO revised their classification of myeloproliferative neoplasms to define Prefibrotic primary myelofibrosis as a ... These mutations are not specific to myelofibrosis, and are linked to other myeloproliferative neoplasms, specifically ... Barosi, Giovanni (2011). "Conventional and Investigational Therapy for Primary Myelofibrosis". Myeloproliferative Neoplasms. pp ...
2008). 'Metabolic Management - Organ Procurement and Preservation For Transplantation. New York: Landes Bioscience Springer. ... Carcinogenesis and Neoplasm) and reference[24]). Furthermore, the ability of HRR to accurately and efficiently repair double- ...
Bernatsky S, Clarke AE, Suissa S (February 2008). "Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis ... Bone Marrow Transplantation. 24 (12): 1367-8. doi:10.1038/sj.bmt.1702097. PMID 10627651.. ... Myeloproliferative neoplasms, including acute leukemia, non-Hodgkin lymphoma and multiple myeloma, occurred in 5 of 119 ...
en:Neoplasm (40) → 신생물 *en:Nephrotic syndrome (38) → 신증후군 *en:Nervous system disease (4) ... en:Heart transplantation (29). *en:Heavy menstrual bleeding (21). *en:Hemodialysis (42) → 혈액투석 ...
Tseng-Tong Kuo, Classification of thymic epithelial neoplasms: a controversial issue coming to an end?, J.Cell.Mol.Med. 5. ... Thymus transplantation in complete DiGeorge syndrome: immunologic and safety evaluations in 12 patients, BLOOD, 1. august 2003 ... Thymus transplantation in complete DiGeorge syndrome: immunologic and safety evaluations in 12 patients, BLOOD, 1. august 2003 ... Using the World Health Organization Classification of Thymic Epithelial Neoplasms to Describe CT Findings, AJR:179, oktoober ...
Neoplasm[edit]. Neoplasms have been described with prolonged exposure to some medications or toxins. Hepatocellular carcinoma, ... Pak, E; Esrason, KT; Wu, VH (2004). "Hepatotoxicity of herbal remedies: an emerging dilemma". Progress in Transplantation. 14 ( ... Those that develop acute liver failure can still recover spontaneously, but may require transplantation if poor prognostic ... Fulminant hepatic failure from drug-induced hepatotoxicity may require liver transplantation. In the past, glucocorticoids in ...
... progressive end-stage renal failure and ischaemic damage caused by renal transplantation or cardiac bypass surgery. GRCh38: ... a marker for studying cellular differentiation in gut epithelial neoplasms". Gastroenterology. 99 (6): 1727-35. PMID 1699834. ...
Chan JK (1998). "Natural killer cell neoplasms". Anat Pathol. 3: 77-145. PMID 10389582. Elaine Sarkin Jaffe; Nancy Lee Harris; ... January 2009). "Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a ... July 2007). "Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from ... May 2008). "Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in ...
ಪ್ರಾಚೀನ ಗ್ರೀಸ್ ನಲ್ಲಿ, ರೋಗಗಳನ್ನು ಗುಣಪಡಿಸುವ ದೇವರು ಎನ್ನಲಾದ ಎಸ್ಕ್ಲೆಪ್ಯಸ್ ದೇವಾಲಯಗಳನ್ನು ನಿರ್ಮಿಸಿ ಅರ್ಪಿಸಲಾಗುತ್ತಿತ್ತು, ಇದನ್ನು ಎಸ್ಕ್ಲೆಪಿಯಾ ಎಂದು ಕರೆಯಲಾಗುತ್ತಿತ್ತು(Greek: Ασκληπιεία, ಅಂದರೆ ಸ್ತುತಿಸುವುದು. ಎಸ್ಕ್ಲೆಪಿಯಿಯೊನ್ Ασκληπιείον )ಗಳು ವೈದ್ಯಕೀಯ ಸಲಹೆ, ತಪಾಸಣೆ ಮತ್ತು ಗುಣಪಡಿಸುವ ಸ್ಥಳಗಳಾಗಿ ಕಾರ್ಯನಿರ್ವಹಿಸುತ್ತಿದ್ದವು.[೫] ಇಂತಹ ದೇವಾಲಯಗಳ ಆವರಣಗಳಲ್ಲಿ ಪ್ರವೇಶಿಸಿದ ರೋಗಿಗಳು ಯಾವದೋ ಒಂದು ಕನಸಿನ ಸ್ಥಿತಿಗೆ ಕಾಲಿಟ್ಟು ...
Ciclosporin is an immunosuppressive agent most often used in organ transplantation that has demonstrated to be effective with ... in association with an underlying neoplasm". A study concluded in 2009, summarized in 2010, surrounded the surgical removal of ...
Multiple myeloma/plasma cell neoplasm. *Myelodysplastic syndromes. *Mucosa-associated lymphoid tissue lymphoma ...
"Islet Cell Tumors of the Pancreas / Endocrine Neoplasms of the Pancreas". The Sol Goldman Pancreas Cancer Research Center. ... Use of liver transplantation may be considered in certain cases of liver metastasis.[81] ... Pancreatic mucinous cystic neoplasms are a broad group of pancreas tumors that have varying malignant potential. They are being ... The third type, pancreatic mucinous cystic neoplasms (MCNs) mainly occur in women, and may remain benign or progress to cancer. ...
Allogeneic stem cell transplantation has been used in rare cases with aggressive systemic mastocytosis in patients deemed to be ... "The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia". Blood. 127 (20): ...
Alternatively, allogeneic bone marrow transplantation may be appropriate for high-risk or relapsed patients.[48] ... Reiter A, Gotlib J (2017). "Myeloid neoplasms with eosinophilia". Blood. 129 (6): 704-714. doi:10.1182/blood-2016-10-695973. ... Younger and healthier patients may choose allogeneic or autologous bone marrow transplantation in the hope of a permanent cure. ... Some patients who successfully respond to treatment also undergo stem cell transplantation to consolidate the response.[56] ...
Salivary gland neoplasms *Benign: Basal cell adenoma. *Canalicular adenoma. *Ductal papilloma. *Monomorphic adenoma ...
More than 1500 different disorders of the skin exist, including cutaneous eruptions ("rashes") and neoplasms. Therefore, ...
Debora Duro, Daniel Kamin (2007). "Overview of short bowel syndrome and intestinal transplantation". Colombia Médica. 38 (1).. ...
Allogenic stem-cell transplantation has the potential for a cure, but is used in a very small percentage of people (and in the ... "Plasma Cell Neoplasms (Including Multiple Myeloma)-Patient Version". NCI. 1980-01-01. Archived from the original on 27 July ... "Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment". National Cancer Institute. 1980-01-01. Retrieved 28 November ... "Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)-Health Professional Version". NCI. July 29, 2016. Archived ...
Transplantation. Decortication. Heart-lung transplant. Chest wall, pleura,. mediastinum,. and diaphragm. pleura/pleural cavity ... Neoplasms - malignant and benign tumors. *Septal hematoma - a mass of (usually) clotted blood in the septum ...
"Haploidentical Stem Cell Transplantation for Refractory/Relapsed Neuroblastoma". Biology of Blood and Marrow Transplantation. ... Nervous tissue tumors/NS neoplasm/Neuroectodermal tumor (ICD-O 9350-9589) (C70-C72, D32-D33, 191-192/225) ... "Bone Marrow Transplantation. 41 (2): 159-65. doi:10.1038/sj.bmt.1705929. PMC 2892221. PMID 18037943.. ... Observation, surgery, radiation, chemotherapy, stem cell transplantation[1]. Prognosis. US five-year survival ~95% (, 1 year ...
... cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type". Ann. Oncol. 21 (5): 1032-40. doi: ... followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma". Ann. Oncol ... "Myeloablative radiochemotherapy followed by autologous peripheral blood stem cell transplantation as first-line therapy in ...
Kidney transplantation, LDL apheresis, Liver biopsy (was redirect, got onto DYK), Nissen fundoplication, Outpatient parenteral ... Myeloproliferative neoplasm, Non-alcoholic fatty liver disease, Pericarditis, Paraneoplastic syndrome, Paroxysmal nocturnal ...
Ovarian neoplasms Germ cell tumor Seen most often in young women or adolescent girls. Other germ cell tumors are: Endodermal ... Lan C, Xiao W, Xiao-Hui D, Chun-Yan H, Hong-Ling Y (December 2008). "Tissue culture before transplantation of frozen-thawed ... Livebirth after orthotopic transplantation of cryopreserved ovarian tissue The Lancet, Sep 24, 2004 ... Oktay K, Oktem O (November 2008). "Ovarian cryopreservation and transplantation for fertility preservation for medical ...
Although allogeneic stem cell transplantation (allo-SCT) is considered potentially curative, very few patients have been re … ... The prognosis for patients with Philadelphia-negative myeloproliferative neoplasms (MPN) who evolve into acute myeloid leukemia ... Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase Leuk Res. 2012 Sep;36(9):1147-51. doi: ... Although allogeneic stem cell transplantation (allo-SCT) is considered potentially curative, very few patients have been ...
In support of improving patient care, Audio Digest Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. The Audio Digest Foundation designates this enduring material for a maximum of {{CurrentLecture.Lecture.Credits , number:2}} AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to {{CurrentLecture.Lecture.Credits}} MOC points [and patient safety MOC credit] in the American Board of Internal Medicines (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the ...
Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: A retrospective ... Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: A retrospective ... The 34 allo-SCT patients had a median age of 41 years (range, 10-70) and received transplantations from sibling (n = 11) or ... Patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) have a poor prognosis with conventional chemotherapy. In the ...
"Neoplasm Transplantation" by people in this website by year, and whether "Neoplasm Transplantation" was a major or minor topic ... "Neoplasm Transplantation" is a descriptor in the National Library of Medicines controlled vocabulary thesaurus, MeSH (Medical ... Below are the most recent publications written about "Neoplasm Transplantation" by people in Profiles. ... Below are MeSH descriptors whose meaning is more general than "Neoplasm Transplantation". ...
Autologous islet transplantation in patients requiring pancreatectomy for neoplasm. / Balzano, Gianpaolo; Piemonti, Lorenzo. ... Autologous islet transplantation in patients requiring pancreatectomy for neoplasm. Current Diabetes Reports. 2014;14(8). 512. ... Autologous islet transplantation in patients requiring pancreatectomy for neoplasm. In: Current Diabetes Reports. 2014 ; Vol. ... Balzano, G., & Piemonti, L. (2014). Autologous islet transplantation in patients requiring pancreatectomy for neoplasm. Current ...
Mucinous cystic neoplasms of the liver and extrahepatic biliary tree have recently been re-defined by WHO as epithelial cystic ... Liver transplantation has been suggested in unresectable cases including recurrent or giant tumours [61, 76]. ... Mucinous cystic neoplasm with high-grade intraepithelial neoplasia. 8470/2. Mucinous cystic neoplasms of the liver with an ... Mucinous cystic neoplasm with low-grade intraepithelial neoplasia. 8470/0. Mucinous cystic neoplasm with intermediate-grade ...
Carcinoembryonic antigen (CEA) was purified from GW-39 human tumor xenografts in hamsters by immunoaffinity chromatography. Binding of the antigen to immobilized monoclonal antibody provided a high degree of purification of CEA in a single step. A recovery of 79% and a 750-fold purification were obtained. The purified CEA has a molecular size of 180 kilodaltons, an isoelectric point of 4.4, and a specific activity of 0.94. About 73% of the radiolabeled GW-39 CEA reacted with goat anti-CEA serum ...
NeoplasmsNeoplasms by SiteNervous System NeoplasmsCentral Nervous System NeoplasmsBrain NeoplasmsCerebral Ventricle Neoplasms ... NeoplasmsBrain Stem NeoplasmsCerebellar NeoplasmsNeurocytomaPinealomaSupratentorial NeoplasmsHypothalamic Neoplasms + ... NeoplasmsBrain Stem NeoplasmsCerebellar NeoplasmsNeurocytomaPinealomaSupratentorial NeoplasmsHypothalamic Neoplasms + ... Nervous System NeoplasmsCentral Nervous System NeoplasmsBrain NeoplasmsCerebral Ventricle NeoplasmsChoroid Plexus Neoplasms + ...
Atypical Myeloproliferative Neoplasms (aMPN) share characteristics of MPN and Myelodysplastic Syndromes. Although abnormalities ... Mouse transplantation. Three sets of experiments were conducted, each with 10 female NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) ... Additional file 2: Table S1. Characteristics of patients with atypical myeloproliferative neoplasms (n = 18). Table S2. ... Mixed Myeloproliferative Neoplasm/myelodysplastic syndrome (MPN/MDS) comprise atypical Chronic Myeloid Leukemia (aCML), Chronic ...
Waldenströms macroglobulinemia & stem cell transplantation. Take Quiz. Characteristics across indolent NHL subtypes. Take Quiz ... AUA Guideline: Follow-up for clinically localized renal neoplasms. Take Quiz. ATA Guidelines: Surgery for thyroid cancer. Take ... AUA Guideline: Follow-up for clinically localized renal neoplasms. Take Quiz. ATA Guidelines: Surgery for thyroid cancer. Take ... AUA Guideline: Follow-up for clinically localized renal neoplasms. Take Quiz. Clinical features and pathology of bladder cancer ...
Allogeneic Stem-Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm. J.C. Ham, J.J.W.M. Janssen, J.E. Boers, ... Allogeneic Stem-Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm. / Ham, J.C.; Janssen, J.J.W.M.; Boers, J ... Allogeneic Stem-Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm. Journal of Clinical Oncology. 2012;30(8 ... title = "Allogeneic Stem-Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm",. author = "J.C. Ham and J.J.W. ...
DNA, Neoplasm. Grant support. *R01 CA155010-02/CA/NCI NIH HHS/United States ... Applications of next-generation sequencing to blood and marrow transplantation.. Chapman M1, Warren EH 3rd, Wu CJ. ... This review discusses the potential impact of this new technology on the field of blood and marrow stem cell transplantation. ... this approach has the potential to contribute important insights into understanding the biologic effects of transplantation. ...
Prevalence of high-risk human papilloma virus among women with hepatitis C virus before liver transplantation. Authors. *. P.A ... Iliana Doycheva, Syed Amer, Kymberly D. Watt, De Novo Malignancies After Transplantation, Medical Clinics of North America, ... Previous article in issue: Renal transplantation from hepatitis B surface antigen (HBsAg)-positive donors to HBsAg-negative ... Previous article in issue: Renal transplantation from hepatitis B surface antigen (HBsAg)-positive donors to HBsAg-negative ...
Risk of myeloid neoplasms after solid organ transplantation. L. M. Morton*, T. M. Gibson, C. A. Clarke, C. F. Lynch, L. A. ...
Other: Haploidentical transplantation of hematopoietic progenitors. Interventional. Phase 1. Phase 2. *Andalusian Initiative ... Transplantation of Hematopoietic Progenitors From Haploidentical Donor With Selective in Vitro Depletion Allo-reactive ... neoplasms [CONDITION] AND child [AGE-GROUP] , Recruiting, Not yet recruiting, Available Studies (1984 records) ... Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies With Alpha Beta TCell and B Cell Depletion Using the ...
Therapy Related Neoplasms in Hematopathology Conference scheduled on June 03-04, 2022 in June 2022 in New York is for the ... Biopsy and transplantation pathology. Immunohistochemistry. Radiofrequency identification and specimen tracking in anatomical ... Therapy Related Neoplasms in Hematopathology. ICTRNH 2022: 16. International Conference on Therapy Related Neoplasms in ... ICTRNH 2022 has teamed up with the Special Journal Issue on Therapy Related Neoplasms in Hematopathology. A number of selected ...
Hematopoietic Stem Cell Transplantation. Humans. Karyotyping. Leukemia, Myeloid / genetics*. Male. Middle Aged. Mutation. ... The only patients who survived were three out of the four who had allogeneic hematopoietic stem cell transplantation (HSCT).. ...
... J Neurooncol. 2001 ... Neoplasm Transplantation * Rats * Rats, Inbred F344 * Tissue Distribution Substances * Copper Radioisotopes * Metalloporphyrins ...
YF vaccine is contraindicated for persons with primary immunodeficiencies, malignant neoplasms, and transplantation (127). ... malignant neoplasms, 5) transplantation, and 6) immune suppression or modulation attributable to current or recent radiation ... Live viral vaccines should be deferred in persons with a history of malignant neoplasm or transplantation until immune function ... solid organ transplant or hematopoietic stem cell transplant recipients within 2 years of transplantation, or persons whose ...
Solid organ transplantation for sickle cell disease. Take Quiz. Hematopoietic stem-cell transplantation for sickle-cell disease ... AUA Guideline: Follow-up for clinically localized renal neoplasms. Take Quiz. ATA Guidelines: Surgery for thyroid cancer. Take ... AUA Guideline: Follow-up for clinically localized renal neoplasms. Take Quiz. ATA Guidelines: Surgery for thyroid cancer. Take ... AUA Guideline: Follow-up for clinically localized renal neoplasms. Take Quiz. Clinical features and pathology of bladder cancer ...
Malignant Neoplasm Procedure: Allogeneic Hematopoietic Stem Cell Transplantation Drug: Atorvastatin Calcium Procedure: ... Neoplasms. Atorvastatin Calcium. Anticholesteremic Agents. Hypolipidemic Agents. Antimetabolites. Molecular Mechanisms of ... Procedure: Peripheral Blood Stem Cell Transplantation Undergo myeloablative allogeneic PBSC transplant. Other Names: *PBPC ... Procedure: Allogeneic Hematopoietic Stem Cell Transplantation Undergo myeloablative allogeneic PBSC transplant. Other Names: * ...
Triple Negative Breast Neoplasms. Breast Neoplasms. Neoplasm, Residual. Neoplasms by Site. Neoplasms. Breast Diseases. Skin ... Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment for Triple Negative Breast Cancer Patients. The safety ... Drug: Carmustine Drug: Cyclophosphamide Drug: Carboplatin Procedure: Autologous Hematopoietic Stem Cell Transplantation Drug: ... Since autologous hematopoietic stem cell transplantation (HSCT) allows the usage of higher doses of chemotherapy, which results ...
Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm, Co-transplantation of Human Ovarian Tissue with ... bone marrow transplantation include Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft- ... Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease. Authors ... Co-transplantation of Human Ovarian Tissue with Engineered Endothelial Cells: A Cell-based Strategy Combining Accelerated ...
Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm, 3D Microtissues for Injectable Regenerative Therapy ... Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm. Thanh Kim Nguyen1, Sarah J. Morse1, Angela G. ... 1Laboratory for Tumor and Transplantation Immunology and Stem Cell Transplantation Program, University Hospital of Cologne, ...
... of all these neoplasms. The remainder of the pathological spectrum includes benign and malignant cell types. ... Consider heart transplantation in those instances in which the benign tumor is too large to resect. Resection is the treatment ... encoded search term (Primary Cardiac Neoplasms) and Primary Cardiac Neoplasms What to Read Next on Medscape ... Primary Cardiac Neoplasms. Updated: Mar 06, 2019 * Author: Mary C Mancini, MD, PhD, MMM; Chief Editor: Eric H Yang, MD more... ...
In addition, patients with "very high risk" disease might be better served by pursuing allogenic stem cell transplantation ... JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths. Ayalew Tefferi. Blood 2012 119:2721-2730; doi: ... JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths Message Subject (Your Name) has forwarded a page ... R723, a selective JAK2 inhibitor, effectively treats JAK2V617F-induced murine myeloproliferative neoplasm. Blood 2011;117(25): ...
Malignant neoplasms. *Transplantation. *Immunosuppressive and immunomodulatory therapies. Precautions (conditions for which the ...
Background Patients with neuroendocrine neoplasms (NEN) develop hepatic metastases in 50-95 %. The aims of this study were to ... 1.Clinic of General, Visceral- and Transplantation SurgeryUniversity Medical Center MainzMainzGermany ... Patients with neuroendocrine neoplasms (NEN) develop hepatic metastases in 50-95 %. The aims of this study were to evaluate the ... Surgical therapy of neuroendocrine neoplasm with hepatic metastasis: patient selection and prognosis. ...
... characterization of a unique neoplasm by histology, immunohistochemistry, ultrastructure, and array-based comparative genomic ... Intrapulmonary ectopic liver after orthotopic heart transplantation.. Next Article:. Pancreatic manifestations of von Hippel- ... The pituicytoma is a rare neoplasm of the sellar region. As illustrated in our 2 cases, a number of features common to the ... Our findings are consistent with those of other investigators and confirm the unique nature of this rare sellar neoplasm. (1,3- ...
Prior stem cell or bone marrow transplantation. Sex/Gender ICMJE Sexes Eligible for Study:. Female. ... Breast Neoplasms Intervention ICMJE *Drug: Palbociclib Palbociclib, 125mg, orally once daily on Day 1 to Day 21 of every 28-day ... Breast NeoplasmsFirst-line Palbociclib and Endocrine Therapy for Patients With HR+/HER2- Advanced Breast Cancer in the Real- ... Breast NeoplasmsA Prospective Registry Study in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer (MBC) ...
  • Peripheral Blood (PB) or Bone Marrow (BM) from unrelated donors can serve as a graft source for hematopoietic cell transplantation. (bioportfolio.com)
  • This concise book examines clinically relevant issues relating to the ways in which bone marrow, cord blood and apheresis products, are processed and stored for the purpose of Hematopoietic Cell Transplantation and Cell Therapy. (frohberg.de)
  • Cytomegalovirus Infection Incidence and Risk Factors Across Diverse Hematopoietic Cell Transplantation Platforms Using a Standardized Monitoring and Treatment Approach: A Comprehensive Evaluation from a Single Institution. (cancer.gov)
  • Malignancies after hematopoietic cell transplantation for primary immune deficiencies: a report from the Center for International Blood and Marrow Transplant Research. (semanticscholar.org)
  • Patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) have a poor prognosis with conventional chemotherapy. (eur.nl)
  • Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study. (mcw.edu)
  • Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is incurable with conventional therapies. (mcw.edu)
  • Objective To investigate the effect of allogeneic hematopoietic stem cell transplantation (allo-HSCT) with intensified conditioning regimen followed by rapidly tapering immunosuppressants and sequential minimal residual disease (MRD)-guided donor lymphocyte infusion (DLI) post- transplantation on outcome of blastic plasmacytoid dendritic cell neoplasm (BPDCN). (bvsalud.org)
  • Blastic plasmacytoid dendritic cell neoplasm: report of a case presenting with lung and central nervous system involvement and review of the literature. (thefreelibrary.com)
  • Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematopoietic malignancy. (thefreelibrary.com)
  • Review on Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), with data on clinics, and the genes involved. (atlasgeneticsoncology.org)
  • Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic neoplasm. (atlasgeneticsoncology.org)
  • The prognosis for patients with Philadelphia-negative myeloproliferative neoplasms (MPN) who evolve into acute myeloid leukemia (AML) or blast phase (MPN-BP) is extremely poor. (nih.gov)
  • Mixed Myeloproliferative Neoplasm/myelodysplastic syndrome (MPN/MDS) comprise atypical Chronic Myeloid Leukemia (aCML), Chronic MyeloMonocytic Leukemia (CMML), Juvenile MyeloMonocytic Leukemia and unclassified MPN/MDS (uMPN/MDS). (biomedcentral.com)
  • The t(6;9)(p22;q34) in myeloid neoplasms: a retrospective study of 16 cases. (biomedsearch.com)
  • Therapy related myeloid neoplasms (t-MN) occur due to direct mutational events of chemotherapeutic agents and radiotherapy. (mjhid.org)
  • Therapy-related myeloid neoplasms are recognized as a separate entity in the World Health Organization (WHO) classification of haematological diseases. (mjhid.org)
  • 1 ] The incidence of therapy-related myeloid neoplasms (t-MN) continue to rise due to the relative prolongation of survival and cure related to chemo- and radio-therapy for primary malignancies, mostly breast cancer and lymphoproliferative diseases. (mjhid.org)
  • Organized in collaboration with: EHA & the EHA Scientific Working Groups on Myelodysplastic Syndromes, Myeloproliferative Neoplasms and Acute Myeloid Leukemia. (ehaweb.org)
  • The first edition of this joint initiative from three Scientific Working Groups aims to provide an overview on the spectrum of myeloid neoplasms (MN) and highlight potential common therapeutic targets. (ehaweb.org)
  • In 2008, the latest WHO classification renamed it as BPDCN as a distinct entity under the category of myeloid neoplasm. (thefreelibrary.com)
  • Chronic myeloid leukaemia after renal transplantation: report of a new case and review of the bibliography," Sangre , vol. 41, no. 5, pp. 391-393, 1996. (hindawi.com)
  • Long-term molecular efficacy and safety of imatinib in a patient with chronic myeloid leukaemia after renal transplantation," Nephrology Dialysis Transplantation , vol. 22, no. 6, pp. 1791-1792, 2007. (hindawi.com)
  • Therapy-related myeloid neoplasm (t-MN) is a distinctive clinical syndrome occurring after exposure to chemotherapy or radiotherapy. (ebscohost.com)
  • Myeloproliferative neoplasms are a group of clonal myeloid cell-derived disorders characterized by myeloproliferation without dysplasia, bone marrow hypercellularity, and predisposition to thrombosis, hemorrhage, and bone marrow fibrosis. (cancernetwork.com)
  • 2007). In 2008, the WHO has placed this neoplasm in the category of acute myeloid leukemia (AML) and related precursor neoplasms (Facchetti et al. (atlasgeneticsoncology.org)
  • This pilot trial offers the unique opportunity for both the treatment of multiple myeloma or systemic AL amyloidosis for which hematopoietic stem cell transplantation would be ordinarily indicated and the reversal of end-stage renal failure, while avoiding the risks associated with long-term standard anti-rejection therapy used in renal transplantation. (clinicaltrials.gov)
  • The primary objectives of this study are to assess renal allograft tolerance (that is, the acceptance of the kidney without the need for anti-rejection therapy), assess anti-tumor response rates in multiple myeloma and AL amyloidosis, and assess complication rates for genetically (HLA) matched related donor combined bone marrow and kidney transplantation using a low dose total body irradiation based preparative regimen. (clinicaltrials.gov)
  • Renal failure is a major complication of multiple myeloma and AL amyloidosis for which the only known cure is allogeneic bone marrow transplantation. (clinicaltrials.gov)
  • Patients with multiple myeloma and AL amyloidosis are excluded from conventional renal transplantation protocols because of their underlying malignancy. (clinicaltrials.gov)
  • A few PTLDs are of T-cell origin, Hodgkin type, or, rarely, plasma cell neoplasms such as multiple myeloma. (medscape.com)
  • To enhance the knowledge of medical society on the mucinous cystic neoplasms of the liver, here we aim to summarise contemporary data on these tumours, including the current definition and classification [ 1 ], the recent molecular genetic findings [ 3 , 4 ] as well as the practical issues of clinical presentation, diagnostic approach, treatment and prognosis. (intechopen.com)
  • Since autologous hematopoietic stem cell transplantation (HSCT) allows the usage of higher doses of chemotherapy, which results in higher cellular destruction with a decrease of hematological toxicity, it is proposed that this procedure is able to improve prognosis in TNBC patients with no pathologic complete response after neoadjuvant chemotherapy. (clinicaltrials.gov)
  • Impact of graft size mismatching on graft prognosis in liver transplantation from living donors. (springermedizin.de)
  • In the present study, we retrospectively analyzed the outcome of patients with BPDCN who underwent allogeneic stem cell transplantation (allo-SCT) or autologous stem cell transplantation (auto-SCT). (eur.nl)
  • This review discusses the potential impact of this new technology on the field of blood and marrow stem cell transplantation. (nih.gov)
  • This phase II trial studies donor atorvastatin treatment for the prevention of severe acute graft-versus-host disease (GVHD) in patients undergoing myeloablative peripheral blood stem cell (PBSC) transplantation. (clinicaltrials.gov)
  • The only patients who survived were three out of the four who had allogeneic hematopoietic stem cell transplantation (HSCT). (biomedsearch.com)
  • 21 Other treatment modalities in MF include allogenic stem cell transplantation, splenectomy, and involved-field radiotherapy. (bloodjournal.org)
  • 21 Unlike drug therapy, allogenic stem cell transplantation is potentially curative in MF, but its overall impact on risk-adjusted survival remains controversial. (bloodjournal.org)
  • To date, there are no data focusing on outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN-U). This study aimed to evaluate outcomes and prognostic factors in patients with MDS/MPN-U after allo-HSCT using Japanese nationwide registry data. (elsevier.com)
  • We describe a cohort of 30 patients, 18 females and 12 males, with median age of 52.5 years (range, 20 to 64), submitted to allogeneic stem cell transplantation (HSCT) in our department between September 1999 and March 2017. (mjhid.org)
  • Haematopoietic stem cell transplantation (HSCT) is a highly specialised procedure used to treat malignancies of the lymphohaematopoietic system as well as some acquired and inherited disorders of the blood. (smw.ch)
  • This analysis by the Swiss Blood Stem Cell Transplantation Group, based on data from 2008-2011, describes, treatment rates in Switzerland for specific indications and compares this with data from Germany, France, Italy and the Netherlands, corrected for the size of the population. (smw.ch)
  • Haematopoietic stem cell transplantation (HSCT) has become an established treatment option for a wide range of haemato-oncological tumours, some solid tumours, and nonmalignant diseases such as bone marrow failure, primary immunodeficiencies and other congenital and acquired disorders [1-2]. (smw.ch)
  • Allogeneic stem cell transplantation (ASCT) is the only current treatment with the potential to cure myelofibrosis (MF), but is also carries a high risk of life-threatening side effects for most MF patients. (llscanada.org)
  • There is no specific age cut-off for stem cell transplantation. (llscanada.org)
  • Reduced-intensity or "nonmyeloblative" allogeneic stem cell transplantation is a type of transplant that uses lower doses of chemotherapy or radiation, and it is being used to treat some patients with leukemia, lymphoma or myeloma. (llscanada.org)
  • The success of reduced-intensity transplantation is a result of the graft-versus-tumor effect of the donor stem cells, rather than of high doses of chemotherapy. (llscanada.org)
  • The numbers of studies and study patients are too small to determine the exact role stem cell transplantation should play in treating MF. (llscanada.org)
  • Clinical trials are under way to study the safety and effectiveness of modified stem cell transplantation. (llscanada.org)
  • What are the complications of nonmyeloablative allogeneic stem cell transplantation (ASCT) for the treatment of renal cell carcinoma (RCC)? (medscape.com)
  • I chose to focus my fellowship on hematologic oncology and blood and bone marrow stem cell transplantation . (mskcc.org)
  • I will be the lead researcher at MSK for multicenter trials focused on myeloma and hematopoietic stem cell transplantation. (mskcc.org)
  • phase II trial is studying how well tandem (two) autologous stem cell transplantation works in treating patients with primary systemic (AL) amyloidosis. (bioportfolio.com)
  • Determine the tolerability of tandem autologous stem cell transplantation in patients with AL amyloidosis. (bioportfolio.com)
  • First transplantation: Patients receive filgrastim (G-CSF) subcutaneously once daily beginning 3 days before the initiation of stem cell collection and continuing until the day before the completion of stem cell collection. (bioportfolio.com)
  • Patients undergo autologous stem cell transplantation (ASCT) on day 0. (bioportfolio.com)
  • Assess expression of emotion, as a function of patient presence, among spousal or other cohabiting caregivers (CG) of post-hematopoietic stem cell transplantation patients. (bioportfolio.com)
  • Subject is not a candidate to undergo allogenic hematopoietic stem cell transplantation (HSCT). (centerwatch.com)
  • 3 Together with the detection of mutant CALR in hematopoietic stem cells, 1 these data define CALR-mutated MPNs as stem cell-derived neoplasms with aberrant and preferential expansion of the megakaryocyte lineage. (hematology.org)
  • Such dynamic prognostic schemes are particularly relevant to decision making about hematopoietic stem cell transplantation. (hematology.org)
  • 15.  Curative treatment options for patients up to 75 years of age consist of adequate conditioning protocols with subsequent allogenic bone marrow or peripheral blood stem cell transplantation. (slideshare.net)
  • Pre-emptive rituximab for Epstein-Barr virus reactivation after haplo-hematopoietic stem cell transplantation. (semanticscholar.org)
  • Epstein-Barr virus (EBV) load in cerebrospinal fluid and peripheral blood of patients with EBV-associated central nervous system diseases after allogeneic hematopoietic stem cell transplantation. (semanticscholar.org)
  • Autologous islet cell transplantation is a procedure performed to prevent or reduce the severity of diabetes after pancreatic resection. (elsevier.com)
  • Autologous islet cell transplantation is being used almost exclusively in patients undergoing pancreatectomy because of painful, chronic pancreatitis, or multiple recurrent episodes of pancreatitis that is not controlled by standard medical and surgical treatments. (elsevier.com)
  • Thus, only a little information on the safety and clinical outcome of patients treated with an ICI after allogeneic haematopoietic cell transplantation (HCT) is currently available. (smw.ch)
  • As treatment options are scarce, many clinicians are therefore considering off-label use of ICIs in relapse after allogeneic haematopoietic cell transplantation (HCT) [ 8 - 10 ]. (smw.ch)
  • When the late Murray Silverstein (1928-1998), a Mayo Clinic physician-scientist par excellence, 1 introduced me to the subspecialty practice of myeloproliferative neoplasms (MPNs) in the early 1990s, hydroxyurea had already been established as the antithrombotic treatment of choice for polycythemia vera (PV). (bloodjournal.org)
  • We show that metabolic alterations in hematopoietic cells are fundamental to the pathogenesis of mutant JAK2 driven myeloproliferative neoplasms (MPNs). (bloodjournal.org)
  • Elucidation of the pathophysiology of myeloproliferative neoplasms (MPNs) has been greatly advanced by the identification of the driver mutations JAK2 and CALR. (nii.ac.jp)
  • Myeloproliferative neoplasms (MPNs) tend to result in EMH. (wikipedia.org)
  • Subject has received allogeneic HSCT or solid organ transplantation. (centerwatch.com)
  • The 34 allo-SCT patients had a median age of 41 years (range, 10-70) and received transplantations from sibling (n = 11) or unrelated donors (n = 23) between 2003 and 2009. (eur.nl)
  • Nineteen allo-SCT patients (56%) received transplantations in first complete remission. (eur.nl)
  • Balzano, G & Piemonti, L 2014, ' Autologous islet transplantation in patients requiring pancreatectomy for neoplasm ', Current Diabetes Reports , vol. 14, no. 8, 512. (elsevier.com)
  • Patients with a history of a renal neoplasm presenting with acute neurological signs or symptoms should undergo which of the following imaging studies? (mdedge.com)
  • Follow-up studies are available from 1 year to 27 years, after 41 patients with FL-HCC were treated with partial hepatectomy (PHx) (28 patients) or liver transplantation (13 patients). (nih.gov)
  • The population consisted of 45 consecutive patients who received an allo-HCT (n = 37) or an auto-HCT (n = 8) regardless of age, pre-transplant therapies, or remission status at transplantation. (mcw.edu)
  • Standard bone marrow transplantation is associated with prohibitive toxicities in patients with end stage renal disease, and is generally not considered an option for those patients. (clinicaltrials.gov)
  • Orthotopic liver transplantation (OLTX) can provide the definitive treatment for patients with ESLD. (medscape.com)
  • Spectrum of CT findings in pediatric patients after partial liver transplantation. (medscape.com)
  • Diagnostic accuracy of contrast-enhanced ultrasound (CEUS) in monitoring vascular complications in patients after liver transplantation - diagnostic performance compared with histopathological results. (medscape.com)
  • Among the areas covered are graft manipulation and methods to control T-cell alloreactivity, the nature of the ideal graft and donor, haploidentical transplantation in pediatric and adult patients with malignant and nonmalignant diseases, immunologic reconstitution following transplantation, complications, and the prevention and treatment of relapse post transplantation. (springer.com)
  • After a median of 36.5 months (range, 4 to 190) from first neoplasm, patients developed t-AML in 19 cases and t-MDS in 11 cases. (mjhid.org)
  • PTLDs develop in approximately 2-3% of patients who undergo immunosuppressive therapy after solid-organ transplantation. (medscape.com)
  • Adult patients with myelodysplasia, leukemia, and non-Hodgkin's lymphoma can be cured by allogeneic bone marrow transplantation (BMT). (knowcancer.com)
  • The assumption that the curative effect of allogeneic transplantation rests in the ability to deliver very high doses of chemoradiotherapy has led to the restriction of allogeneic transplantation to those recipient patients whose overall status would permit the use of such intense conditioning. (knowcancer.com)
  • Two recent published studies investigating non-myeloablative allo-transplantation in standard risk patients revealed an extremely low rate of transplant related complications and mortality. (knowcancer.com)
  • In this study, we will assess the safety and efficacy of nonmyeloablative transplantation in patients with HIV infection. (knowcancer.com)
  • to compare the outcome of liver transplantation for hepatocarcinoma in submitted or not to locoregional treatment and downstaging regarding survival and risk of recurrence in transplant waiting list patients. (scielo.br)
  • retrospective study of patients with hepatocarcinoma undergoing liver transplantation in the metropolitan region of São Paulo, between January 2007 and December 2011, from a deceased donor. (scielo.br)
  • About 90% of HCCs develop in cirrhotic livers, mainly associated with hepatitis B or C. Liver transplantation (LTx) is now the best treatment for patients with cirrhosis and HCC 1 . (scielo.br)
  • Graft weight/recipient body weight ratio (G/R ratio) in living-related liver transplantation for pediatric patients: abdominal wall closure in cases with a large G/R ratio. (springermedizin.de)
  • Two patients died of transplantation-related causes, and eight died from progressive disease. (medscape.com)
  • Second transplantation: Within 6-12 months after the first ASCT, patients not achieving a complete response receive high-dose melphalan IV over 20 minutes on days -3 and -2 and a second ASCT on day 0. (bioportfolio.com)
  • transplantation may help improve the quality of life of both the caregivers and the patients. (bioportfolio.com)
  • Evidence for this is found in the much higher risk of non-Hodgkin's lymphoma among patients with congenital immunodeficiency syndromes and in patients with iatrogenically induced immunosuppression in conjunction with organ transplantation or cancer treatment. (bmj.com)
  • A new class of drugs has redefined treatment for patients with myeloproliferative neoplasms by easing their symptom burden while extending their lives. (mdanderson.org)
  • Our aim is to provide updated results on the worldwide use of autologous HSC transplantation (AHSCT) in T1D patients, to evaluate potential adverse events, and to explore the successes and potential pitfalls of this novel therapy. (diabetesjournals.org)
  • Dr. Jennifer Kanakry engages in clinical research related to allogeneic bone marrow transplantation for patients with primary immunodeficiency diseases (PID). (cancer.gov)
  • In collaboration with investigators from the National Institute of Allergy and Infectious Diseases (NIAID), Dr. Kanakry is leading a clinical trial at the NCI of allogeneic bone marrow transplantation for PID, with the aims of reducing the toxicities of transplant, expanding donor options with the use of half-matched donors, and improving the immune function and health of patients with PID. (cancer.gov)
  • Some patients are younger than 40 years old, and even children with this neoplasm have been reported. (atlasgeneticsoncology.org)
  • We evaluated 18,014 patients who underwent allogeneic bone marrow transplantation (BMT) at 235 centers worldwide to examine the incidence of and risk factors for posttransplant lymphoproliferative disorders (PTLD). (semanticscholar.org)
  • A less toxic bone marrow transplantation protocol, utilizing low dose total body irradiation and anti-thymocyte globulin, combined with renal transplantation, could provide an opportunity for cure of the myeloma or amyloidosis and correction of end stage renal disease. (clinicaltrials.gov)
  • Complete cytogenietic remission with imatinib mesylate treatment in chronic myelogenous leukemia (CML) developed after renal transplantation," Clinical Nephrology , vol. 64, no. 4, pp. 324-326, 2005. (hindawi.com)
  • Remisión molecular de una leucemia mieloide crónica en un paciente con Segundo trasplante renal y hepatitis," Nefrologia , vol. 6, pp. 604-607, 2009. (hindawi.com)
  • For lymphoid neoplasms, e.g. lymphoma and leukemia , clonality is proven by the amplification of a single rearrangement of their immunoglobulin gene (for B cell lesions) or T cell receptor gene (for T cell lesions). (wikipedia.org)
  • 1) Later, the European Organisation for Research and Treatment of Cancer (EORTC) classification of cutaneous lymphoma renamed it as CD4+CD56+ hematodermic neoplasm in 2005. (thefreelibrary.com)
  • 1994), BPDCN has been known with various names, including agranular CD4+ natural killer (NK) leukemia, CD4+/CD56+ hematodermic neoplasm, and blastic NK lymphoma (Facchetti et al. (atlasgeneticsoncology.org)
  • 2007). The exact incidence might be difficult to determine due to the various definitions of BPDCN as a leukemia or a skin lymphoma prior to the 2008 WHO inclusion of this neoplasm into the AML and related precursors neoplasms (Facchetti et al. (atlasgeneticsoncology.org)
  • In the realm of kidney transplantation, tolerance means that the recipient is unable to detect the donor transplant kidney as foreign, and therefore the recipient is unable to reject the kidney. (clinicaltrials.gov)
  • Secondary neoplasm refers to any of a class of cancerous tumor that is either a metastatic offshoot of a primary tumor, or an apparently unrelated tumor that increases in frequency following certain cancer treatments such as chemotherapy or radiotherapy . (wikipedia.org)
  • Bone marrow transplantation , 33 (12), 1215-1218. (elsevier.com)
  • Successful allogeneic bone marrow transplantation using. (pagepress.org)
  • Of the myeloproliferative neoplasms, myelofibrosis - marked by an uncontrolled growth of bone marrow cells, reactive bone marrow fibrosis and a subsequent lack of red blood cells - is the most aggressive. (mdanderson.org)
  • Successful Bone Marrow Transplantation for XMEN: Hemorrhagic Risk Uncovered. (cancer.gov)
  • Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. (semanticscholar.org)
  • Solid cancers after bone marrow transplantation. (semanticscholar.org)
  • Although the overall incidence of primary cardiac neoplasms is low (0.0001-0.5% in autopsy series), these cardiac tumors provide unique diagnostic and therapeutic challenges. (medscape.com)
  • Hepatocarcinoma (HCC) is the most common malignant neoplasm of the liver and the sixth leading cause of cancer mortality worldwide, with an incidence of 750,000 new cases per year. (scielo.br)
  • 2008). Recent reports in the incidence, indicate that this neoplasm accounts for 0.4% of all hematologic neoplasms, 0.7% of the primary cutaneous lymphomas, and less than 1% of all acute leukemias (Facchetti et al. (atlasgeneticsoncology.org)
  • Current Research and Scholarly Interests Clinicopathologic studies in endometrial carcinoma, ovarian neoplasms, and soft tissue tumors. (stanford.edu)
  • A neoplasm can be benign , potentially malignant, or malignant ( cancer ). (wikipedia.org)
  • Malignant neoplasms are commonly called cancer. (wikipedia.org)
  • In particular, I am interested in soft tissue and genitourinary neoplasms, especially prostate cancer. (stanford.edu)
  • This significant symptom reduction is more than palliation - it is life altering," said Srdan Verstovsek, M.D., Ph.D. , a professor of Leukemia at MD Anderson Cancer Center, who has led and is leading numerous trials of new treatments for myeloproliferative neoplasms. (mdanderson.org)
  • The classical Philadelphia chromosome-negative myeloproliferative neoplasms (MPN), which include essential thrombocythemia, polycythemia vera, and myelofibrosis (MF), are in a new era of molecular diagnosis, ushered in by the identification of the JAK2 V617F and c MPL mutations in 2005 and 2006, respectively, and the CALR mutations in 2013. (jnccn.org)
  • Few studies have reported EBV - PTLD in pediatric solid-organ transplantation recipients. (nebraska.edu)
  • PTLDs are an uncommon but serious complication of immunosuppressive therapy after solid-organ transplantation. (medscape.com)
  • Chronic immunosuppressive therapy, as used in organ transplantation, may perturb the immunosurveillance ability of the host, making the patient more susceptible to virus-associated malignancies. (semanticscholar.org)
  • auto-SCT, n = 5) were identified in the European Group for Blood and Marrow Transplantation registry. (eur.nl)
  • Applications of next-generation sequencing to blood and marrow transplantation. (nih.gov)
  • The most common primary cardiac tumor is the atrial myxoma, which accounts for 40-50% of all these neoplasms. (medscape.com)
  • Consider heart transplantation in those instances in which the benign tumor is too large to resect. (medscape.com)
  • Neoplasm is an abnormal growth of tissue which, if it forms a mass, is commonly referred to as a tumor . (wikipedia.org)
  • Current English, however, both medical and non-medical, uses tumor as a synonym for a neoplasm (a solid or fluid-filled cystic lesion that may or may not be formed by an abnormal growth of neoplastic cells) that appears enlarged in size. (wikipedia.org)
  • Current Research and Scholarly Interests Dr. Kambham's research interests primarily involve medical diseases and transplantation pathology of the kidney and liver. (stanford.edu)
  • Epstein-Barr virus-associated hepatic smooth muscle neoplasm in a cardiac transplant recipient. (semanticscholar.org)
  • Atypical Myeloproliferative Neoplasms (aMPN) share characteristics of MPN and Myelodysplastic Syndromes. (biomedcentral.com)
  • What are the causes of end-stage liver disease necessitating orthotopic liver transplantation (OLTX)? (medscape.com)
  • Boraschi P, Donati F, Rossi M, Ghinolfi D, Filipponi F, Falaschi F. Role of MDCT in the detection of early abdominal complications after orthotopic liver transplantation. (medscape.com)
  • We systematically reviewed the literature on definitions and outcomes of large-for-size (LFS) syndrome in orthotopic liver transplantation (LT). (springermedizin.de)
  • Host immunosuppression is increasingly recognized as a significant risk factor for the development of a primary neoplasm. (semanticscholar.org)
  • Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. (nih.gov)
  • Primary neoplasms are subdivided into benign and malignant forms. (nih.gov)
  • In addition, relapse of primary myelodysplasia rarely occurs after 5 years from the time of allogeneic transplantation. (elsevier.com)
  • Primary neoplasms may arise from endocardium, valvular structures, primitive tissue rests, and the conduction system. (medscape.com)
  • transplantation may be effective treatment for primary systemic (AL) amyloidosis. (bioportfolio.com)
  • benign neoplasms , in situ neoplasms , malignant neoplasms , and neoplasms of uncertain or unknown behavior. (wikipedia.org)
  • Potentially-malignant neoplasms include carcinoma in situ . (wikipedia.org)
  • Allogeneic blood or marrow transplantation (BMT) is a potentially curative treatment for many of these diseases. (cancer.gov)
  • Secondary or metastatic neoplasms arise from hematologic spread of the originating tissue. (medscape.com)
  • Other lymphoid neoplasms, such as those that arise from mucosal-associated lymphoid tissue (MALTomas), have recently been recognized in transplant recipients, and their relationship to PTLD is uncertain. (medscape.com)
  • [5] Malignant neoplasms are also simply known as cancers and are the focus of oncology . (wikipedia.org)
  • EBV - posttransplantation lymphoproliferative disorders (PTLDs) are rare compared with EBV + PTLDs, occur later after transplantation, and have a poor response to treatment. (nebraska.edu)
  • Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis. (cancer.gov)
  • Mucinous cystic neoplasms of the liver and extrahepatic biliary tree have recently been re-defined by WHO as epithelial cystic tumours with ovarian-type mesenchymal stroma. (intechopen.com)
  • Currently, mucinous cystic neoplasms of the liver are defined as epithelial cystic tumours associated with ovarian-type mesenchymal stroma. (intechopen.com)